Podcasts about icahn school

Why are more people becoming afraid of vaccines than the diseases vaccines were created to prevent? The answer is not simply a lack of information. In many ways, vaccines have become victims of their own success.For decades, widespread vaccination helped push diseases like measles, polio, pertussis, and smallpox out of everyday life. Many of us no longer live with the visible fear of these infections, their complications, or the way they can destabilize families, communities, and healthcare systems.But when the disease feels distant, the vaccine can start to feel like the bigger threat.That shift is now changing public health.Rather than assuming vaccine hesitancy is only about ignorance or defiance, we need to look more carefully at:• why people can become more suspicious of vaccines when they no longer see the diseases vaccines helped control• How misinformation, fear, personal experience, politics, history, and social media can shape health decisions• Why highly educated people can still be vulnerable to vaccine misinformation• how confusing a side effect, adverse event, or normal immune response with a true allergy can create long-term fear• Why egg allergy is no longer the vaccine barrier many people still believe it is• And how declining vaccination rates can allow diseases like measles and pertussis to reemergeVaccine education has to move beyond simply telling people what to do. We need clearer, more compassionate conversations that acknowledge fear while helping people separate facts from fiction.In this upcoming episode, I'm joined by Dr. Joyce Yu, associate professor of pediatrics and director of the Food Allergy Program at Columbia University Irving Medical Center.Together, we explore:What is driving the rise of vaccine hesitancyWhy vaccine-preventable diseases can return when communities let their guard downHow allergists help patients understand whether a vaccine reaction is truly an allergyAnd why rebuilding trust requires listening, clarity, and evidence-based conversationIf you or someone you love has ever felt uncertain, afraid, or confused about vaccines, allergic reactions, side effects, or conflicting health information, this conversation offers a grounded look at how fear spreads, how misinformation takes hold, and why protecting public health depends on rebuilding trust.Guest BioDr. Joyce Yu is an associate professor of pediatrics and director of the Food Allergy Program at Columbia University Irving Medical Center. She is an allergy and immunology specialist with clinical and scientific expertise in food allergy, immunology, vaccine-related concerns, and immune system function. Dr. Yu received her medical education at the Icahn School of Medicine at Mount Sinai, completed her residency at Northwestern/Lurie Children's Hospital, and completed her fellowship in Allergy and Immunology at Mount Sinai. Her postdoctoral work focused on toll-like receptor signaling and memory B cell development, mechanisms that are closely connected to how the immune system develops lasting protection. She is a fellow of both the American College of Allergy, Asthma & Immunology and the American Academy of Allergy, Asthma & Immunology. She is also a former president of the New York Allergy and Asthma Society and has held leadership roles within the Clinical Immunology Society. Connect with Dr. Yu on LinkedIn.About Your HostHosted by Dr. Deepa Grandon, MD, MBA, a triple board-certified physician with over 23 years of experience working as a Physician Consultant for influential organizations worldwide. Dr. Grandon is the founder of Transformational Life Consulting (TLC) and an outspoken faith-based leader in evidence-based lifestyle medicine.Disclaimer ​​TLC is presenting this podcast as a form of information sharing only. It is not medical advice or intended to replace the judgment of a licensed physician. TLC is not responsible for any claims related to procedures, professionals, products, or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services, or methods that might be referenced.Work With Me Learn More About My Soon-to-Launch Telemedicine PlatformExciting news. My virtual medical platform is launching soon! If you're looking for personalized, evidence-based care in allergy, immunology, and lifestyle medicine, stay tuned.Visit drdeepa-tlc.org and click on “Learn More” to join the waitlist and be the first to receive updates about services, membership options, and launch details.Precision care. Personalized guidance. Wherever you are.DevotionalsWant to receive a devotional every week from Dr. Deepa? Devotionals are dedicated to providing you with a moment of reflection, inspiration, and spiritual growth each week, delivered right to your inbox. Visit drdeepa-tlc.org to subscribe for free.Trauma CoursesReady to deepen your understanding of trauma and kick-start your healing journey? Explore a range of online and onsite courses designed to equip you with practical and affordable tools. From counselors, ministry leaders, and educators to couples, parents, and individuals seeking help for themselves, there's a powerful course for everyone. Browse all the courses now to start your journey.

This week, our coverage of the Consortium of MS Centers annual meeting continues with my guest, Dr. Stephen Krieger. In a wide-ranging conversation, Dr. Krieger offers a very encouraging clinical trial update, shares his thoughts on what treating someone living with advanced MS ought to look like, and points out potential obstacles to implementing the updated criteria for diagnosing MS.  Dr. Krieger is a Professor of Neurology at the Icahn School of Medicine at Mount Sinai in New York, and a Multiple Sclerosis Specialist at the Corinne Coldsmith Dickinson Center for MS. We're also sharing results of a study that revealed some surprising connections between caffeine, alcohol, opioids, and MS symptoms. And if you're living with MS and you're the parent of a young child, we'll tell you about a book that belongs on your bookshelf. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: We're at the CMSC annual meeting with Dr. Stephen Krieger  :22 Study reveals the connection between caffeine, alcohol, and opioids and your MS symptoms    1:12 My Superhero with Wheels is the book you need if you're living with MS and have young children  5:15 Dr. Stephen Krieger discusses exciting clinical trial results, treating people with advanced MS, and potential challenges in implementing the updated criteria for diagnosing MS   8:39 Share this episode  30:22 Next week  30:41 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/458 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes at www.RealTalkMS.com STUDY: Daily Temporal Associations Between Psychoactive Substances and Fatigue, Pain, Stress, and Depressive Symptoms in People with Multiple Sclerosis https://archives-pmr.org/article/S0003-9993(26)00035-3/fulltext BOOK: My Superhero with Wheels https://amazon.com/My-Superhero-wheels-True-Story/dp/B0GWVGSWX5/ref=sr_1_1 JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on X, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 458 Guest: Dr. Stephen Krieger Privacy Policy

Robert Rapaport, MD, Professor of Pediatric Endocrinology, and Director of the Comprehensive Growth Center at the Icahn School of Medicine, Mount Sinai Medical Center, New York City, discusses the causes of growth hormone deficiency and its treatment. Growth failure in children is a considerable challenge for parents and pediatricians, with clinical and social stigma implications that may be avoided with early diagnosis.The most important issue in young patients with growth failure is to detect it early, according to Dr. Rapaport. “As soon as you see a major deviation from the [expected growth chart] norm, act on it, even at age 2,” he emphasized, “because we know that best outcomes result from early detection.” A growth failure diagnosis is delayed or underdiagnosed in minority groups; it is underdiagnosed in girls relative to boys. In most cases, children are referred to the Comprehensive Growth Center by pediatricians and primary care physicians, and it should be monitored from birth. Growth failure in children can be caused by growth hormone (GH) deficiency, malnutrition, celiac disease, pituitary tumor (which suppresses the release of growth hormone) or a very rare genetic deletion. Once the potentially nonendocrine causes of GH deficiency are excluded, then causes related to the hypothalamus–pituitary-thyroid axis should be investigated, said Dr. Rapaport. Growth hormone stimulation testing and low blood levels of insulin-like growth factor (IGF) and IGF-binding protein concentrations can help confirm GH deficiency as the cause. However, low IGF-1 levels can also be caused by excessively high GH levels. In children diagnosed with GH deficiency, weekly GH injections are typically prescribed. In addition to monitoring these children for potential side effects of the GH injections, Dr. Rapoport recommended that they should undergo lab testing for IGF-1 blood concentrations every 3 to 6 months, until the bones fuse (signaling the conclusion of growth).

You can find more here from Alan:https://alanrozanski.com/⁠https://www.linkedin.com/in/alanrozanski/Longevity isn't just about cholesterol, blood pressure, or diet.In this episode, Dr. Alan Rozanski — cardiologist, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, Director of Nuclear Cardiology at Mount Sinai Morningside, and recently featured in TIME — explains why healthy aging is about far more than traditional heart health metrics.Dr. Rozanski is helping redefine cardiovascular care by focusing on the bigger drivers of vitality and longevity: strength, stress resilience, mindset, purpose, and social connection.He shares his research-backed framework, the Six Domains of Optimal Health & Vitality, and how high-achieving professionals can use it to stay sharp, energetic, and resilient long term.In this episode, we explore:• Why cholesterol and blood pressure don't tell the full story of heart health• The real drivers of longevity and healthy aging• How stress resilience impacts cardiovascular health• The connection between mindset, purpose, and long-term vitality• Why strength and social connection are critical for aging well• Practical ways to protect your heart and extend your performance lifespanIf you're a driven professional who wants to maintain energy, leadership capacity, and mental sharpness for decades — this conversation is essential.

Christopher Romero, MD, a pediatric endocrinologist at Mount Sinai Medical Center, New York City, and Associate Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai discusses arginine vasopressin deficiency. The name of the rare disease central diabetes insipidus was changed in 2024 to better reflect its etiology.Central diabetes insipidus, a rare disease, is unrelated to the common medical problem diabetes mellitus, other than they are both problems related to endocrinologic dysfunction. Whereas diabetes mellitus involves pancreatic function and the production of the hormone insulin, central diabetes insipidus involves the pituitary gland and regulation of the hormone vasopressin. Dr. Romero stated that a new name for central diabetes insipidus was introduced in 2024—arginine vasopressin deficiency (AVP-D) to reflect the difference and relieve misconceptions caused by the traditional naming. The central issue with AVP-D is the function of antidiuretic hormone, which regulates water concentrations in the body. Pediatric and adult patients with this vasopressin deficiency (which mediates antidiuretic hormone levels) excrete more urine than patients without the deficiency. “It causes these patients to drink more, to make up for the water loss,” said Dr. Romero, “resulting in kids being thirstier and having to use the bathroom more often.” As a result, AVP-D can lead to weight loss and loss of appetite, dehydration, and electrolyte abnormalities. He also pointed out that the abnormal cycle of drinking and urination in children interferes with school work and performance. “Unless you're aware of [AVP-D], you may miss the diagnosis,” said Dr. Romero. The pituitary gland is involved with so many functions, and symptoms only slowly evolve. Issues with the onset of puberty and growth may hint at the pituitary source of the problem. Historically, treatment was managed with an oral formulation of vasopressin, which was first available in the 1970s. An intravenous form was available in inpatient settings. A nasal spray formulation was subsequently developed, and is useful particularly with older children. Dr. Romero pointed out, figuring out the correct dosage for an individual pediatric patient is key; every child with AVP-D is different in terms of how much water they lose during the drinking–urination cycle. “Even though the oral form was effective, only two dosages were available. You have to titrate the dose to balance the water loss,” he emphasized.The introduction of Desmoda in February 2026, an oral solution of desmopressin acetate 0.05 mg/mL, allows for easier titration. The solution may be easier to take than the pills for young children, and caregivers may have a better idea of precisely how much medication the patient is getting. For those reasons, Dr. Romero believes this formulation may be the best option for young pediatric patients with AVP-D. 

Wie kam es zum Ausbruch des Hantavirus in Südamerika? Um welchen Stamm des Virus handelt es sich und was hat das alles mit der Lüftungssituation auf Kreuzfahrtschiffen zu tun. Ein Podcast von Pragmaticus.Das Thema:Es waren Meldungen, die an die Corona-Zeit erinnerten. Auf dem Kreuzfahrtschiff Hondius starb Anfang Mai ein Mann an einer Variante des Hantavirus, wenig später seine Frau. Das Schiff wurde in Quarantäne gesetzt, die WHO eingeschalten und schnell hatten Virologen eruiert, dass es sich um die Andes-Variante aus der Familie der Hantaviren handelt.Seine Besonderheit: Es springt nicht nur von Nagetieren auf Menschen, sondern dann auch von Mensch zu Mensch. „Es ist eine Neuweltvariante und kommt immer wieder in Südamerika vor“, resümiert der Viren-Experte Florian Krammer, der den Hantaviren seine Berufswahl zu verdanken hat. In seiner Heimat in Steiermark werden immer wieder Menschen infiziert, wenn sie „zum Beispiel Garagen auskehren und auf diese Weise den pulverisierten Kot von Rötelmäusen einatmen“, erzählt Krammer. Einige von ihnen erkrankten schwer, andere nicht.Mittlerweile forscht Krammer an Medikamenten und Impfstoffen für Erkrankte, eine Frage der finanziellen Mittel. Aber es geht auch um die Infektionsgefahr etwa auf Kreuzfahrtschiffen. Ihn als Virologe brächten keine zehn Pferde auf so ein Schiff, zu groß ist dort die Infektionsgefahr. Unser Gast in dieser Folge: Florian Krammer hat an der Universität für Bodenkultur in Wien studiert und seine Postdoc-Ausbildung im Labor von Peter Palese an der Icahn School of Medicine at Mount Sinai, New York absolviert. Dort beschäftigte er sich vor allem mit dem Influenzavirus. Im Jahr 2014 wurde er unabhängiger Principal Investigator und ist derzeit Mount-Sinai-Stiftungsprofessor für Vakzinologie an der Icahn School of Medicine at Mount Sinai. Außerdem ist Krammer seit 2024 Professor für Infektionsmedizin am Ignaz-Semmelweis-Institut der Medizinischen Universität Wien. Er konzentriert sich auf das Verständnis der Mechanismen von Interaktionen zwischen Antikörpern und viralen Oberflächenglykoproteinen und auf die Umsetzung dieser Arbeit in neuartige, breit schützende Impfstoffe und Therapeutika. Sein Hauptfokus ist das Influenzavirus, aber er arbeitet auch an Coronaviren, Flaviviren, Hantaviren, Filoviren und Arenaviren. Er hat mehr als 400 Arbeiten zu diesen Themen veröffentlicht.Dies ist ein Podcast von Der Pragmaticus. Sie finden uns auch auf Instagram, Facebook, LinkedIn und X (Twitter).

Welcome to Fertility & Sterility Roundtable, hosted by Dr. Emily Barnard and Dr. Ben Peipert! Each week, we will host a discussion with the authors of "Views and Reviews" and "Fertile Battle" articles published in a recent issue of Fertility & Sterility.  Today, we will be discussing the Fertile Battle episode from the April 2026 edition of Fertility and Sterility entitled "Is Concurrent Gestational Surrogacy an Ethical Practice?" Concurrent surrogacy involves two gestational carriers being engaged simultaneously—or whose pregnancies overlap—to allow a single intended parent or couple to have children born without the usual spacing between births  Dr. Michelle Bayefsky is a second year Reproductive Endocrinology and Infertility fellow at the Icahn School of Medicine at Mount Sinai. She has written a book and more than 30 peer-reviewed papers on issues related to reproductive ethics and fertility preservation. She is currently a member of the ASRM Ethics Committee. For the purposes of this discussion, Dr. Bayefsky authored the Pro side of the argument that concurrent gestational surrogacy is an ethical practice.  Dr. Caroline Violette is a second year Reproductive Endocrinology & Infertility Fellow at Brown University. Prior to fellowship, Dr. Violette obtained her medical degree from Emory University School of Medicine and completed her residency in Obstetrics and Gynecology at the University of Southern California. Her research interests include oncofertility and addressing healthcare disparities related to access to fertility treatment in the United States. For the purposes of this discussion, Dr. Violette authored the "con" side of the argument that these concurrent surrogacy arrangements are unethical.  Dr. Arthur Caplan is a Professor and founding head of the Division of Medical Ethics at NYU School of Medicine in New York City. Dr. Caplan has served on a number of national and international committees, including chair of the Advisory Committee to the United Nations on Human Cloning, a member of the advisory committee to the International Olympic Committee on genetics and gene therapy, and co-director of the Joint Council of Europe/United Nations Study on Trafficking in Organs and Body Parts. He is the author or editor of thirty-five books and over 890 papers in peer reviewed journals. Dr. Caplan authored the pro side of the argument.  Read the Fertile Battle from Volume 125, Issue 4 p598-604 in the April 2026 issue View Fertility and Sterility at https://www.fertstert.org/  

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Dr. Gilbert Tang, Editor-in-Chief of Journal of the American College of Cardiology (JACC): Case Reports, professor in the Department of Cardiovascular Surgery at the Icahn School of Medicine at Mount Sinai, surgical director of the Structural Heart Program at Mount Sinai Health System, and the director of Structural Heart Education at the Mount Sinai Fuster Heart Hospital in New York, NY, USA. They were joined by Drs. Mateo Marin-Cuartas, associate editor of JACC: Case Reports, CTSNet JANS Editor, and cardiac surgeon at Leipzig Heart Center, Germany, and Tsuyoshi Kaneko, Chair of American College of Cardiology (ACC) Cardiac Surgery Member Section and Chief of Cardiac Surgery at Washington University in St. Louis, MO, USA, to discuss JACC: Case Reports. Chapters 00:00 Intro 01:45 Instructional Video Competition 05:30 JANS 1, Lung Cancer Metastasis 09:08 JANS 2, Uncorrected Pectus 11:29 JANS 3, Ambulatory VV Life Support 13:38 JANS 4, EuroSCORE II 14:28 Video 1, TAVR Removal Double Patch 16:09 Video 2, ROK Procedure AF 17:46 Video 3, RATS Lobectomy 19:11 JACC Case Reports 35:28 Upcoming Events 36:03 Career Center They discussed the mission of the journal and the types of submissions it receives. They also covered the types of cases accepted and the various categories within the journal has, such as the "How We Did It" section. Additionally, they talked about the upcoming partnership between JACC: Case Reports and the ACC, as well as past collaborations that JACC has undertaken. Dr. Marin-Cuartas shared insights about his role as an associate editor and highlighted the most interesting case he has encountered in JACC: Case Reports. Furthermore, Dr. Kaneko discussed being the Chair of the ACC Cardiac Surgery Member Section. Joel also highlights recent JANS articles on the evolutionary characterization of lung cancer metastasis, the impact of severe uncorrected pectus excavatum on outcomes after aortic surgery in Marfan syndrome, determining an optimal central cannulation strategy for ambulatory veno-venous extracorporeal life support, and refitting EuroSCORE II for 120-day mortality after coronary artery bypass grafting using nationwide registry data. In addition, Joel explores complex imaging TAVR removal double patch double valve, RATS extended left upper lobectomy with intrapericardial vascular control and bronchoplasty, and ROK procedure for the treatment of atrial fibrillation. Before closing, Joel highlights upcoming events in CT surgery.   JANS Items Mentioned Evolutionary Characterization of Lung Cancer Metastasis Impact of Severe Uncorrected Pectus Excavatum on Outcomes After Aortic Surgery in Marfan Syndrome Determining an Optimal Central Cannulation Strategy for Ambulatory Veno-Venous Extracorporeal Life Support Refitting EuroSCORE II for 120-Day Mortality After Coronary Artery Bypass Grafting Using Nationwide Registry Data CTSNet Content Mentioned Complex Imaging TAVR Removal Double Patch Double Valve RATS Extended Left Upper Lobectomy With Intrapericardial Vascular Control and Bronchoplasty ROK Procedure for the Treatment of Atrial Fibrillation Other Items Mentioned JACC: Case Reports 2026 Instructional Video Competition Winners Career Center CTSNet Events   Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Dr. Jeanine Cook-Garard learns about Colorectal Cancer, because a new study by the American Cancer Society shows that -- while overall cancer deaths in people younger than 50 in the United States has decreased since their last study -- only colorectal cancer mortality has increased, advancing it from the fifth most common cause of cancer death in the early 1990s to the first in 2023, seven years earlier than predicted. She speaks with Dr. Pascale M. White, a Fellow of the American College of Gastroenterology, and Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai.

Robert Pass is Professor of Pediatrics and Chief of the Division of Pediatric Cardiology at the Icahn School of Medicine at Mount Sinai and Mount Sinai Kravis Children's Hospital. He is Co-Director of the Mount Sinai Kravis Children's Heart Center and Director of Pediatric Electrophysiology at the Mount Sinai Health System. In addition to his exceptional clinical work as an electrophysiologist, he is the host of the very successful medical education podcast Pediheart: Pediatric Cardiology Today.Learning Objective: By the end of this podcast, listeners should be able to discuss an evidence-based and expert-guided approach to the evaluation and management of high-grade atrioventricular block in children.References:PediHeart Podcast with Robert Passhttps://www.youtube.com/@RobertPassPediheart Kusumoto et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. J Am Coll Cardiol. 2019 Aug 20;74(7):932-987.Questions, comments or feedback? Please send us a message at this link (leave email address if you would like us to relpy) Thanks! -Alice & ZacSupport the showHow to support PedsCrit:Please complete our Listener Feedback SurveyPlease rate and review on Spotify and Apple Podcasts!Donations are appreciated @PedsCrit on Venmo , you can also support us by becoming a patron on Patreon. 100% of funds go to supporting the show.Please remember that all content during this episode is intended for educational and entertainment purposes only. It should not be used as medical advice. The views expressed during this episode by hosts and our guests are their own and do not reflect the official position of their institutions. If you have any comments, suggestions, or feedback-you can email us at pedscritpodcast@gmail.com.  You can also check out our website at http://www.pedscrit.com. Thank you for listening to this episode of PedsCrit!

“Backwater to Blockbuster,” the first de novo book published by the Cancer History Project, traces the evolution of St. Jude Children's Research Hospital to its current status of a powerhouse of research in pediatric cancer.In a conversation moderated by Deborah Doroshow, the book's co-authors Charles J. Sherr and William E. Evans discuss how their book project began, their collaborative writing process.As long-time leaders, Sherr and Evans were a part of the institution's rise and thus speak authoritatively about the institutional culture, leadership philosophy, and scientific ambition that shaped St. Jude.Sherr, who joined St. Jude in 1983, served as chair of Tumor Cell Biology Department and Herrick Foundation Endowed Chair at St. Jude. Evans first came to St. Jude as a student in 1972 and served in many key positions including that of St. Jude's fifth director and CEO.Their book, published by the Cancer History Project, is available at no charge here>LINK

The new Netflix documentary “The Plastic Detox” follows six couples struggling with unexplained infertility, asking them to cut plastic from their lives to see if that could help them conceive. While not a scientific study, the film explores the intriguing possibility that reducing everyday plastic exposure can actually improve our health. But how likely is this? We talk with the fertility researcher and one of the couples in the documentary to hear what they think we should — and should not — take away from the experiment. Guests: Shanna Swan, professor of environmental medicine, Icahn School of Medicine; founder and director, Action Science Initiative Monique Tavares, owner, San Ramon construction company BL Pavers; participant, “The Plastic Detox” Jasmine McDonald, associate professor of epidemiology, Mailman School of Public Health at Columbia University Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses KRAS updates from the American Association for Cancer Research (AACR) 2026 Annual Meeting with Dr. Deborah Doroshow, Dr. David S. Hong, and Dr. Jonathan Riess. Guests: Deborah Doroshow, MD, PhD Associate Professor of Medicine, Hematology/Oncology Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai David S. Hong, MD Douglas E. Johnson Endowed Professor Deputy Chair, Department of Investigational Cancer Therapeutics [A Phase I Program] Division of Cancer Medicine Clinical Medical Director, Clinical and Translational Research Center The University of Texas MD Anderson Cancer Center Jonathan Riess, MD Associate Professor of Medicine, UC Davis Comprehensive Cancer Center Director of Thoracic Oncology, University of California, Davis

In this episode we are exploring 2 recent Journal of Genetic Counseling articles on the topic of insurance coverage and concerns about genetic discrimination. Segment 1: Cardiovascular genetic counselor decision making about discussing life insurance with patients Guest Bios: Sara Cherny has almost 20 years of experience as a genetic counselor in the Chicagoland area, specializing in cardiovascular genetics for the past decade. Her wide range of experience allows her to provide comprehensive care for patients in the Cardiovascular Genetics Clinic at Ann & Robert H. Lurie Children's Hospital, where she engages in patient care, program development, and research. Her research focuses on trends in cardiovascular genetics, access to genetic services, genetic privacy, and genetic discrimination. She is involved in advocacy work with the Illinois Society of Genetic Professionals (ISGP) and the Pediatric and Congenital Electrophysiology Society (PACES). Sara loves how her work combines science and patient care, and is committed to scientific discovery that both improves patient experience and moves the field forward.  Sarah Jurgensmeyer Langas is a genetic counselor in the Heart Center at the Ann and Robert H. Lurie Children's Hospital of Chicago with a specific focus in congenital heart disease, aortopathies, and Williams syndrome. Sarah is an Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine and enjoys teaching and providing clinical supervision to genetic counseling graduate students and medical students. Sarah is also active in the Illinois Society of Genetic Professionals, currently serving on the Advocacy Committee and previously serving as President in 2024. She was the recipient of the 2023 ACMG Foundation Carolyn Mills Lovell Genetic Counselor Award and is passionate about expansion of genetic services to more patient populations. https://www.instagram.com/luriechildrensheartcenter/ https://www.instagram.com/sara_cherny/   In this segment we discuss: - How life insurance considerations arise in genetic counseling, particularly in cardiovascular genetics, and how conversations vary based on patient knowledge, phenotype, and age. - Findings that genetic counselors are more likely to address life insurance with phenotype-positive and adult patients, while time constraints and clinical context can limit these discussions. - How fear of genetic discrimination impacts patient decision-making, including declining testing, alongside reports of real-world insurance denial. - Challenges in balancing transparency with avoiding unnecessary fear, and the need for better education, standardized guidance, and further research in this space. Segment 2: Understanding GINA through case examples: A guide for US-based genetic counselors   Guest Bios: Anya Prince is the David H. Vernon Professor at the University of Iowa College of Law. Her research and teaching interests focus on genetic discrimination and privacy. @anyaprince.bsky.social   Misha Rashkin, MS, CGC, graduated from the Icahn School of Medicine at Mount Sinai Masters program in genetic counseling in 2013. He is a clinical genetic counselor in oncology at Stanford HealthCare, focusing on hereditary malignant hematology. He chaired the NSGC public policy committee in 2018, and lectures about GINA and privacy to genetic counseling graduate programs.   In this segment we discuss: - Ongoing misconceptions and knowledge gaps about GINA, including what it does and does not protect - The value of case-based learning to clarify complex legal and clinical scenarios in genetic counseling - Nuances in GINA's protections, especially around manifested conditions and evolving genetic technologies - Challenges in counseling patients about discrimination risk, balancing information, and navigating policy gaps like life and disability insurance coverage Resources: Germline genetic testing and privacy concerns in patients with mesothelioma from Genetics in Medicine Genetic Privacy in the US: Insurance and Law Enforcement Use website   Would you like to nominate a JoGC article to be featured in the show? If so, please fill out this nomination submission form here. Multiple entries are encouraged including articles where you, your colleagues, or your friends are authors.   Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.    For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.    Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.    DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. Our current intern is Stephanie Schofield.

What if depression and anxiety are not just disorders of the brain, but conditions shaped by the entire body?In this episode of Research Renaissance, host Deborah Westphal speaks with Dr. Scott Russo, Director of the Brain Body Research Institute at Mount Sinai, about a major shift underway in mental health science. His work challenges the long-standing brain-only model of psychiatric illness and explores how inflammation, immune signaling, and organ systems interact with the brain to shape mood, resilience, and disease risk.From gut health to traumatic injury, this conversation reveals why mental health research is moving toward an integrative “systems biology” approach that could redefine treatment in the next decade.Key TakeawaysMental illnesses often coexist with medical conditions, suggesting they are whole-body disorders rather than isolated brain diseases.Chronic inflammation may be a shared biological driver across conditions ranging from depression to cardiovascular disease.Signals from peripheral organs can influence emotional states, meaning some emotions may originate in the body before being processed by the brain.Environmental exposures, infections, and life experiences may account for the majority of mental health risk, with genetics contributing a smaller portion.Emerging therapies may target immune pathways or body-brain signaling rather than neurotransmitters alone.Collaboration across disciplines is essential to advancing mental health research, yet institutional silos still limit innovation.About the GuestDr. Scott Russo is Director of the Brain Body Research Institute at the Icahn School of Medicine at Mount Sinai. His work focuses on understanding how immune, metabolic, and neural systems interact to influence psychiatric disorders and resilience.Resources & MentionsBrain-Body Research Institute at Mount SinaiResearch on inflammation and psychiatric diseaseAdvances in vagus nerve stimulation therapiesIf you enjoyed this episode:Follow Research Renaissance for more conversations shaping the future of health science.Share this episode with a colleague exploring neuroscience, psychiatry, or integrative medicine.Leave a review to help others discover the show.To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org. Technical Podcast Support by Jon Keur at Wayfare Recording Co.

On this episode of the Live Greatly podcast, Kristel Bauer sits down with cardiologist Dr. Alan Rozanski to explore how to support heart health, longevity, and overall well-being through simple, science-backed habits. Together, they discuss how daily behaviors—from movement and nutrition to mindset—play a powerful role in long-term health. Dr. Rozanski shares insights from his integrative approach to cardiology, including the surprising impact of prolonged sitting, the importance of resistance training, and how small "exercise snacks" throughout the day can support energy and vitality. They also dive into the role of optimism in supporting both emotional well-being and physical health, along with approachable strategies you can begin using right away to feel better, think clearer, and live with more energy. If you're looking to elevate your health in a sustainable, empowering way, this episode is packed with insights to support you. Key Takeaways From This Episode: How to support heart health and longevity through everyday habits Why prolonged sitting has been called "the new smoking" — and what to do instead The benefits of resistance training for long-term health and vitality How to incorporate "exercise snacks" into your day to boost energy and performance Tips to boost optimism for physical and mental health Simple, sustainable strategies to support nutrition, movement, and overall well-being ABOUT DR. ALAN ROZANSKI Dr. Alan Rozanski is a distinguished Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Director of Nuclear Cardiology at Mount Sinai St. Luke. He has devoted his career to pioneering research that empowers individuals to cultivate vitality, sustain optimism, and master their emotional well-being as core components of lasting health. Merging his deep expertise in cardiology, health psychology, and behavioral medicine with his innovative framework, The Six Domains of Health, Dr. Rozanski offers a fresh, integrative perspective on how we can live longer, feel better, and approach life with greater emotional resilience. His voice is a compelling one in today's conversation on preventive medicine and total well-being. Connect with Dr. Alan Rozanski   Website: https://alanrozanski.com/ LinkedIn: https://www.linkedin.com/in/alanrozanski/  About the Host of the Live Greatly podcast, Kristel Bauer: Kristel Bauer is a corporate wellness and performance expert, keynote speaker and TEDx speaker supporting organizations and individuals on their journeys for more happiness and success. She is the award-winning author of Work-Life Tango: Finding Happiness, Harmony, and Peak Performance Wherever You Work (John Murray Business November 19, 2024). With Kristel's healthcare background, she provides data driven actionable strategies to leverage happiness and high-power habits to drive growth mindsets, peak performance, profitability, well-being and a culture of excellence. Kristel's keynotes provide insights to "Live Greatly" while promoting leadership development and team building. Kristel is the creator and host of her global top self-improvement podcast, Live Greatly. She is a contributing writer for Entrepreneur, and she is an influencer in the business and wellness space having been recognized as a Top 10 Social Media Influencer of 2021 in Forbes. As an Integrative Medicine Fellow & Physician Assistant having practiced clinically in Integrative Psychiatry, Kristel has a unique perspective into attaining a mindset for more happiness and success. Kristel has presented to groups from the American Gas Association, Bank of America, bp, Commercial Metals Company, General Mills, Northwestern University, Santander Bank and many more. Kristel's work has been featured in Forbes and she has had multiple TV appearances including NBC News Daily, ABC News Live, FOX Weather, ABC 7 Chicago, WGN Daytime Chicago and more. Kristel lives in the Chicago, IL area and she can be booked for speaking engagements worldwide. To Book Kristel as a speaker for your next event, click here. Website: www.livegreatly.co  Follow Kristel Bauer on: Instagram: @livegreatly_co  LinkedIn: Kristel Bauer Twitter: @livegreatly_co Facebook: @livegreatly.co Youtube: Live Greatly, Kristel Bauer To Watch Kristel Bauer's TEDx talk of Redefining Work/Life Balance in a COVID-19 World click here. Click HERE to check out Kristel's corporate wellness and leadership blog Click HERE to check out Kristel's Travel and Wellness Blog Disclaimer: The contents of this podcast are intended for informational and educational purposes only. Always seek the guidance of your physician for any recommendations specific to you or for any questions regarding your specific health, your sleep patterns changes to diet and exercise, or any medical conditions.  Always consult your physician before starting any supplements or new lifestyle programs. All information, views and statements shared on the Live Greatly podcast are purely the opinions of the authors, and are not medical advice or treatment recommendations.  They have not been evaluated by the food and drug administration.  Opinions of guests are their own and Kristel Bauer & this podcast does not endorse or accept responsibility for statements made by guests.  Neither Kristel Bauer nor this podcast takes responsibility for possible health consequences of a person or persons following the information in this educational content.  Always consult your physician for recommendations specific to you.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Joseph Goldberg, MD Our understanding of depression has evolved over the past several decades, leading us to some potential new treatment options that focus on neuroplasticity, chemical imbalance, and negative cognitive biases. Learn more about the history of depression treatment approaches and the emerging concept of neuroplasticity with Dr. Charles Turck and Dr. Joseph Goldberg, Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai in New York City.

In this episode, Meena Bansal, MD, FAASLD - System Chief, Division of Liver Diseases Director, MASH/NASH Center of Excellence, Icahn School of Medicine at Mount Sinai, discusses newly approved therapies for MASH and the growing impact of GLP-1 medications. She also shares insights on personalized treatment, early intervention, and the future of liver disease care.

In this episode, Meena Bansal, MD, FAASLD - System Chief, Division of Liver Diseases Director, MASH/NASH Center of Excellence, Icahn School of Medicine at Mount Sinai, discusses newly approved therapies for MASH and the growing impact of GLP-1 medications. She also shares insights on personalized treatment, early intervention, and the future of liver disease care.

In our April episode, gastroenterologist Dr. Preeti Mehta explained the connection between a healthy gut and a healthy mind. She also talked about the role stress plays in irritable bowel syndrome (IBS), a common digestive disorder that can often be managed with lifestyle changes. In this month's Key Note, Dr. Mehta discusses two other conditions that can be confused with IBS—and why getting the diagnosis right really matters. The Takeaway We want to hear from you! Please complete our survey: 1199SEIUBenefits.org/member-feedback. Drop us a line at our social media channels: Facebook // Instagram // YouTube. Find out where your health stands by making an appointment with your primary care physician. Don't have one? Find one at our Provider Directory: www.1199SEIUBenefits.org/find-a-provider. Visit the Healthy Living Resource Center for wellness tips, information and resources; www.1199SEIUBenefits.org/healthyliving. Get to know your numbers at www.1199SEIUBenefits.org/healthyhearts. Need support managing chronic conditions such as type 2 diabetes, hypertension or overweight? Learn about our partnerships: visit www.1199SEIUBenefits.org/the-choice-is-yours/ Browse healthy recipes and meal-prep tips at www.1199SEIUBenefits.org/food-as-medicine. Get inspired by fellow members through our Members' Voices series: www.1199SEIUBenefits.org/healthyliving/membervoices. Stop by our Benefits Channel to join webinars on building healthy meals, managing stress and more: www.1199SEIUBenefits.org/videos. Visit our  YouTube channel to view a wide collection of healthy living videos: www.youtube.com/@1199SEIUBenefitFunds/playlists. Sample our wellness classes to exercise body and mind: www.1199SEIUBenefits.org/wellnessevents   Guest Bio Preeti Mehta, MD, is a board-certified gastroenterologist and hepatologist with over 25 years of experience in digestive health care. She serves as Vice President of Digestive Disease Care, a multi-physician gastroenterology practice, and oversees two large Ambulatory Surgical Centers serving patients across Long Island and Queens. Dr. Mehta earned her Doctor of Medicine degree from the Icahn School of Medicine at Mount Sinai and completed her internship and residency in Internal Medicine at North Shore University Hospital in Manhasset, New York. She went on to complete a Research Fellowship in Hepatology at NewYork-Presbyterian Hospital, in affiliation with Weill Medical College of Cornell University and Rockefeller University. She also completed a Clinical Fellowship in Gastroenterology and Hepatology and an Advanced Endoscopy Fellowship in Endoscopic Ultrasound at the State University of New York. She is a member of the American College of Gastroenterology, the American Society for Gastrointestinal Endoscopy and the American Association for the Study of Liver Diseases.

In this very special episode, Dr. Jacob Ham and associate therapist Elizabeth Ferreira join me to discuss their work as trauma therapists. They talk openly about the messy, unglamorous reality of struggle, mistakes, and repair that characterizes trauma work, its nature as both art and science, how their work has changed over time, and what they've learned along the way. Topics include self-disclosure, working with shame and grief, dealing with situations where the client wants an apology, the difference between trauma work and more manualized approaches, therapist training and supervision, and “polishing the mirror.”  I loved listening to Dr. Ham and Elizabeth talk during this episode. It's a truly unique one, and I hope you enjoy it.  About our Guest: Dr. Jacob Ham is a clinical psychologist, Associate Clinical Professor at the Icahn School of Medicine at Mount Sinai, and the Director of the Center for Complex Trauma there. He's the clinician featured in Stephanie Foo's wonderful book What My Bones Know. Key Topics :  0:00: Introduction and nervousness 6:21: The role of disclosure 11:34: Mistakes, rupture, and repair 23:20: Sharing grief 33:04: Supervision and parallel process  36:29: Therapy as an art form 47:52: Structure, flexibility, and 'opening the hand' 52:50: A listener question: how to let it all go 1:02:40: How trauma work changes you 1:07:46: Recap Support the Podcast: We're on Patreon! If you'd like to support the podcast, follow this link. SponsorsGo to Zocdoc.com/BEING to find and instantly book a top-rated doctor today. Learn more about your ad choices. Visit megaphone.fm/adchoices

The wellness industry has a problem, and Ezekiel Emanuel is one of the few people willing to call it out. In his new book, Eat Your Ice Cream: A Contrarian’s Guide to Living Longer, Healthier, and Happier, the bioethicist, oncologist, and former White House health advisor challenges both the influencers selling unproven supplements and the culture of wellness-as-self-punishment. In this episode, Emanuel makes a compelling research-backed case that the single most powerful determinant of health, longevity, and happiness is social connection, not sleep scores, protein intake, or VO2 max. Drawing on the Harvard Adult Development Study, the longitudinal study, going strong after 88 years, and other research worldwide, he explains why loneliness is biologically dangerous, and why doctors almost never ask about it. He also makes important points about retirement. When 40 hours of purposeful work becomes 40 hours of passive television, the brain pays a price. Emanuel argues that retirement requires deliberate design to replace the cognitive challenge, social contact, and structured schedule that work once provided. And he offers Ben Franklin, inventor of bifocals at 79, and still inventing at 81, as a model for what staying fully alive in later life actually looks like. Ezekiel Emanuel joins us from Washington, DC. ________________________ For More on Ezekiel Emanuel Eat Your Ice Cream: A Contrarian’s Guide to Living Longer, Healthier, and Happier Website ________________________ Bio Ezekiel J. Emanuel, MD, PhD, is the Vice Provost for Global Initiatives and the Diane v.S. Levy and Robert M. Levy University Professor. An oncologist and world leader in health policy and bioethics, he is a Special Advisor to the Director General of the World Health Organization, Senior Fellow at the Center for American Progress, and member of the Council on Foreign Relations. He was the founding chair of the Department of Bioethics at the National Institutes of Health and held that position until August 2011. From 2009 to 2011, he served as a Special Advisor on Health Policy to the Director of the Office of Management and Budget and National Economic Council. In this role, he was instrumental in drafting the Affordable Care Act. Dr. Emanuel is the most widely cited bioethicist in history. He has over 350 publications and has authored or edited 15 books. His recent publications include Which Country Has the World's Best Health Care (2020), Prescription for the Future (2017), Reinventing American Health Care: How the Affordable Care Act Will Improve our Terribly Complex, Blatantly Unjust, Outrageously Expensive, Grossly Inefficient, Error Prone System (2014) and Brothers Emanuel: A Memoir of an American Family (2013). In 2008, he published Healthcare, Guaranteed: A Simple, Secure Solution for America, which included his own recommendations for health care reform.Dr. Emanuel regularly contributes to The New York Times, The Washington Post, The Wall Street Journal, and The Atlantic and often appears on BBC, NPR, CNN, MS NOW and other media outlets. He has received numerous awards, including election to the Institute of Medicine (IOM) of the National Academy of Science and awards from the American Academy of Arts and Sciences, the Association of American Physicians, and the Royal College of Medicine (UK). He has been named a Dan David Prize Laureate in Bioethics and is a recipient of the AMA-Burroughs Wellcome Leadership Award, the Public Service Award from the American Society of Clinical Oncology, the Lifetime Achievement Award from the American Society of Bioethics and Humanities, the Robert Wood Johnson Foundation David E. Rogers Award, the President's Medal for Social Justice from Roosevelt University, and the John Mendelsohn Award from the MD Anderson Cancer Center, as well as honorary degrees from Icahn School of Medicine at Mount Sinai, Union Graduate College, the Medical College of Wisconsin, and Macalester College. Dr. Emanuel is a graduate of Amherst College. He holds a M.Sc. from Oxford University in Biochemistry and received his M.D. from Harvard Medical School and a Ph.D. in political philosophy from Harvard University. ________________________ Retirement Podcast Conversations You’ll Also Love   The Good Life – Marc Schulz, PhD Retiring: Creating a Life That Works for You – Teresa Amabile How Not to Age – Dr. Michael Greger _________________________ About The Retirement Wisdom Podcast There are many podcasts on retirement, often hosted by financial advisors with their own financial motives, that cover the money side of the street. This podcast is different. You'll get smarter about the investment decisions you'll make about the most important asset you'll have in retirement: your time. About Retirement Wisdom I help people who are retiring, but aren't quite done yet, discover what's next and build their custom version of their next life. A meaningful retirement doesn't just happen by accident. Schedule a call today to discuss how the Designing Your Life process created by Bill Burnett & Dave Evans can help you make your life in retirement a great one — on your own terms. About Your Podcast Host Joe Casey is an executive coach who helps people design their next life after their primary career and create their version of The Multipurpose Retirement.™ He created his own next chapter after a 26-year career at Merrill Lynch, where he was Senior Vice President and Head of HR for Global Markets & Investment Banking. Joe has earned Master's degrees from the University of Southern California in Gerontology (at age 60), the University of Pennsylvania, and Middlesex University (UK), a BA in Psychology from the University of Massachusetts at Amherst, and his coaching certification from Columbia University. In addition to his work with clients, Joe hosts The Retirement Wisdom Podcast, ranked in the top 1% globally in popularity by Listen Notes, with over 2 million downloads. Business Insider recognized Joe as one of 23 innovative coaches who are making a difference. He's the author of Win the Retirement Game: How to Outsmart the 9 Forces Trying to Steal Your Joy. __________________________ Wise Quotes On Wellness “Wellness should be about joie de vivre — about joy in life. It should not be only self-deprivation…Most of wellness is about don’t do stupid stuff — and most of it, we already know.” On Retirement “Most people when 40 hours of work drops out, 40 hours of TV comes in. Very passive. Not very intellectually challenging. That’s not retirement — that’s a slow decline…We don’t spend nearly enough time thinking about the brain part of retirement. Your brain is probably more important than your money.” On Willpower vs. Habits “If you have to use your willpower every time you do something, you can forget it. You have to make the wellness activity part of your habit. Doing it three to four times a week for about six weeks, that’s about what you need for a new activity to become ingrained.”  

This month, Health Is the Key does double duty as we spotlight National Stress Awareness Month and IBS Awareness Month. If you're wondering what stress has to do with irritable bowel syndrome and other digestive disorders, you'll be glad you tuned in. We are lucky to be joined by Dr. Preeti Mehta, a gastroenterologist and founder of the private practice Digestive Disease Care. Dr. Mehta explains the effect the brain has on the digestive system and vice-versa. She also shares practical lifestyle habits that can support long-term gut health.    The Takeaway  We want to hear from you! Please complete our survey: 1199SEIUBenefits.org/member-feedback. Drop us a line at our social media channels: Facebook // Instagram // YouTube. Find out where your health stands by making an appointment with your primary care physician. Don't have one? Find one at our Provider Directory: www.1199SEIUBenefits.org/find-a-provider.  Visit the Healthy Living Resource Center for wellness tips, information and resources; www.1199SEIUBenefits.org/healthyliving. Get to know your numbers at www.1199SEIUBenefits.org/healthyhearts.  Need support managing chronic conditions such as type 2 diabetes, hypertension or overweight? Learn about our partnerships: visit www.1199SEIUBenefits.org/the-choice-is-yours/ Browse healthy recipes and meal-prep tips at www.1199SEIUBenefits.org/food-as-medicine.  Get inspired by fellow members through our Members' Voices series: www.1199SEIUBenefits.org/healthyliving/membervoices.  Stop by our Benefits Channel to join webinars on building healthy meals, managing stress and more: www.1199SEIUBenefits.org/videos. Visit our  YouTube channel to view a wide collection of healthy living videos: www.youtube.com/@1199SEIUBenefitFunds/playlists. Sample our wellness classes to exercise body and mind: www.1199SEIUBenefits.org/wellnessevents.   Guest Bio  Preeti Mehta, MD, is a board-certified gastroenterologist and hepatologist with over 25 years of experience in digestive health care. She serves as Vice President of Digestive Disease Care, a multi-physician gastroenterology practice, and oversees two large Ambulatory Surgical Centers serving patients across Long Island and Queens.  Dr. Mehta earned her Doctor of Medicine degree from the Icahn School of Medicine at Mount Sinai and completed her internship and residency in Internal Medicine at North Shore University Hospital in Manhasset, New York. She went on to complete a Research Fellowship in Hepatology at NewYork-Presbyterian Hospital, in affiliation with Weill Medical College of Cornell University and Rockefeller University. She also completed a Clinical Fellowship in Gastroenterology and Hepatology and an Advanced Endoscopy Fellowship in Endoscopic Ultrasound at the State University of New York. She is a member of the American College of Gastroenterology, the American Society for Gastrointestinal Endoscopy and the American Association for the Study of Liver Diseases. 

Join us for the discussion on the treatment and management of hyperphosphatemia or high phosphorus levels in the blood, a common challenge experienced by people living with chronic kidney disease on dialysis. This episode is supported by Ardelyx.   In this episode we heard from:  Dr. Annabel Biruete is an Assistant Professor and Registered Dietitian in the Department of Nutrition Science at Purdue University and an Adjunct Assistant Professor in the Division of Nephrology at the Indiana University School of Medicine. Her broad clinical interest is nutrition in kidney diseases. Dr. Biruete's research aims to study the effects of nutritional and pharmacological therapies for chronic kidney disease on the gastrointestinal tract and gut microbiome. Additionally, Dr. Biruete is interested in improving outcomes in the Hispanic/LatinX community living with chronic kidney disease, primarily targeting nutritional interventions using language- and culturally-concordant lifestyle educational materials. Melissa Tuff has been living with chronic kidney disease for 30 years. Her journey began in 1996 on her 17th birthday when she “crashed” into dialysis following a misdiagnosed UTI. She was on in-center hemodialysis for 9 and a half years until she received a life-changing kidney transplant that lasted 11 years. In 2016 her kidney rejected and since then, she continued treatment with 4 years of peritoneal dialysis and 6 years of solo home hemodialysis. She utilizes her Social Media pages for digital education & patient empowerment by hosting educational TikTok Live sessions while performing solo home hemodialysis; offering real-time insight into dialysis life and empowering others to take an active role in their treatment. Her goal is to build a support community and reduce the stigma around kidney disease by fostering open, educational, and uplifting conversations online while providing resources and guidance as to how one can live long and well on dialysis. Dr. Jaime Uribarri is a practicing nephrologist and clinical investigator in NYC. He has been in the Icahn School of Medicine at Mount Sinai, NYC, since 1990, where he is currently Professor of Medicine and Director of the Renal Clinic and the Home Dialysis Program at the Mount Sinai Hospital. In parallel with his clinical activities, Dr Uribarri has been very active in clinical investigation for more than 40 years. His main areas of research have been on acid-base and fluid and electrolytes disorders as well as nutrition in chronic kidney disease and diabetic patients. He has published well over 200 peer-reviewed papers, written many chapters in books and edited several books. He has lectured extensively on these research topics in New York City as well as in national and international meetings.   Additional Resources High Phosphorus Mineral and Bone Disorder (CKD-MBD) Secondary Hyperparathyroidism (SHPT) ASN Kidney Health Guidance on Potassium and Phosphorus Food Additives   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.

In our March episode, we truly celebrated National Kidney Month with Dr. Kristin Meliambro, an Associate Professor in the Department of Medicine at the Icahn School of Medicine at Mount Sinai. Dr. Meliambro discussed the many vital jobs kidneys perform, the causes and symptoms of kidney disease, and preventive measures that can help keep them healthy. In this month's Key Note, Dr. Meliambro walks us through the latest innovations that are making dialysis – the necessary treatment for those living with Stage 5 kidney disease – more manageable.   The Takeaway We want to hear from you! Please complete our survey: org/member-feedback. Drop us a line at our social media channels: Facebook// Instagram // YouTube. Find out where your health stands by making an appointment with your primary care physician. Don't have one? Find one at our Provider Directory: www.1199SEIUBenefits.org/find-a-provider. Visit the Healthy Living Resource Center for wellness tips, information and resources; 1199SEIUBenefits.org/healthyliving. Get to know your numbers at www.1199SEIUBenefits.org/healthyhearts. Need support managing chronic conditions such as type 2 diabetes, hypertension or overweight? Learn about our partnerships: visit www.1199SEIUBenefits.org/the-choice-is-yours/ Browse healthy recipes and meal-prep tips at 1199SEIUBenefits.org/food-as-medicine. For additional information and support, visit the National Kidney Foundation website, at Kidney.org, and the American Association of Kidney Patients, at www.aakp.org. For information about kidney donation, visit the Nation Kidney Registry page at KidneyRegistry.com Get inspired by fellow members through our Members' Voices series: 1199SEIUBenefits.org/healthyliving/membervoices. Stop by our Benefits Channel to join webinars on building healthy meals, managing stress and more: 1199SEIUBenefits.org/videos. Visit our YouTube channel to view a wide collection of healthy living videos: youtube.com/@1199SEIUBenefitFunds/playlists. Sample our wellness classes to exercise body and mind: 1199SEIUBenefits.org/wellnessevents. Guest Bio Kristin Meliambro, MD, is an Associate Professor in the Department of Medicine, Division of Nephrology at the Icahn School of Medicine at Mount Sinai. She earned her medical degree from the Icahn School of Medicine at Mount Sinai, and she completed both her internal medicine residency and clinical and research nephrology fellowships at the Mount Sinai Hospital. In addition to treating patients with a wide range of kidney diseases in diverse clinical settings, Dr. Meliambro is an NIH-funded physician-investigator who conducts basic and translational research with a focus on mechanisms of kidney podocyte injury and novel disease therapies. She is the co-Director of the Nephrology Division's Renal Biorepository, which banks biological specimens and collects clinical data from patients starting at the time of kidney biopsy and continuing longitudinally. She also actively participates as a PI and Co-Investigator in clinical trials testing novel agents for glomerular diseases. Dr. Meliambro also has a strong record of research mentorship of Associate Researchers and graduate/medical students in her lab, the majority of whom have been women and from under-represented minorities in science and medicine. Dr. Meliambro sees patients with a variety of kidney diseases, and she has a particular clinical interest in glomerular diseases. Her clinical responsibilities include the care of outpatients at the Mount Sinai Doctors nephrology practice, hemodialysis patients at Central Park Dialysis Center and inpatients at the Mount Sinai Hospital, where she also teaches and supervises nephrology fellows on the inpatient nephrology services.

Ageing with HIV brings new challenges. Even with effective ART, people ageing with HIV face increased risk of parkinsonism. Eran F Shorer from the Icahn School of Medicine at Mount Sinai joins us to explore the latest research on brain changes, motor slowing, and the need for better diagnosis and treatment.https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00262-0/fulltextContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Did you know that fertility rates have dropped 50% in the last 5 decades, and more and more people are requiring help to grow their family? Some are calling it "Spermageddon." I'm not one to run with fantastical headlines, but the truth is that we are facing an infertility epidemic. And, this is all heartbreaking for the people dealing with infertility, and for us as a society.   Today, I'm honored to be joined by Dr. Shanna Swan on The Egg Whisperer Show to talk about this upsetting truth. Dr. Swan is one of the world's leading environmental and reproductive epidemiologists and a Professor of environmental medicine and public health at the Icahn School of Medicine at Mount Sinai in New York City. An award-winning scientist, her work examines the impact of environmental exposures including chemicals such as phthalates and Bisphenol A, on men's and women's reproductive health and the neurodevelopment of children. She just recently published her book, "Countdown: How Our Modern World Is Threatening Sperm Counts, Altering Male and Female Reproductive Development, and Imperiling the Future of the Human Race."   We will be talking about the data and information that Dr. Swan has gathered, the environmental factors that are playing a role, and what we can do to reverse some of the impact. I hope you'll tune in and share this information far and wide. CountMeIn on changing this epidemic - and thank you for writing your eye-opening new book, Dr. Swan.   Read the full show notes on Dr. Aimee's website Subscribe to my YouTube channel for more fertility tips! Join Egg Whisperer School Checkout the podcast Subscribe to the newsletter to get updates Dr. Aimee Eyvazzadeh is one of America's most well known fertility doctors. Her success rate at baby-making is what gives future parents hope when all hope is lost. She pioneered the TUSHY Method and BALLS Method to decrease your time to pregnancy. Learn more about the TUSHY Method and find a wealth of fertility resources at www.draimee.org.

Ana Fernández Sesma, Catedrática y directora del Departamento de Microbiología de la Facultad de Medicina Icahn en el Mount Sinai, en  Nueva York, y su colega Adolfo García Sastre, director del Global Health & Emerging Pathogens Institute en la misma Icahn School of Medicine at Mount Sinai, protagonizan Ágora. Ambos científicos, virólogos e inmunólogos de reputación mundial, participan en el Zaragoza en las Jornadas de Actualización en Gripe, un encuentro organizado por CSL Seqirus, uno de los mayores productores mundiales de vacunas de la gripe, la Asociación Española de Vacunología y la Asociación Nacional de Enfermería y Vacunas, entre otras. Ágora queda con ellos para conversar sobre virus, virus de la gripe sobre todo, patógenos, pandemias, vacunas y Salud Pública.

This National Kidney Month, we celebrate the unsung heroes of the human body. Kidneys do so much more than filter blood (they've been described as the body's “cleaning crew” and “inventory managers”), so keeping them functioning well is vital to our overall health. Joining us to sing the praises of kidneys – and learn how to keep them healthy – is Dr. Kristin Meliambro, an Associate Professor in the Department of Medicine, Division of Nephrology at the Icahn School of Medicine at Mount Sinai. Dr. Meliambro walks us through the many essential jobs kidneys do for us and breaks down the various causes of kidney disease. She also shares practical lifestyle habits that support long-term kidney health.   The Takeaway We want to hear from you! Please complete our survey: org/member-feedback. Drop us a line at our social media channels: Facebook// Instagram // YouTube. Find out where your health stands by making an appointment with your primary care physician. Don't have one? Find one at our Provider Directory: www.1199SEIUBenefits.org/find-a-provider. Visit the Healthy Living Resource Center for wellness tips, information and resources; 1199SEIUBenefits.org/healthyliving. Get to know your numbers at www.1199SEIUBenefits.org/healthyhearts. Need support managing chronic conditions such as type 2 diabetes, hypertension or overweight? Learn about our partnerships: visit www.1199SEIUBenefits.org/the-choice-is-yours/ Browse healthy recipes and meal-prep tips at 1199SEIUBenefits.org/food-as-medicine. For additional information and support, visit the National Kidney Foundation website, at Kidney.org, and the American Association of Kidney Patients, at www.aakp.org. For information about kidney donation, visit the Nation Kidney Registry page at KidneyRegistry.com Get inspired by fellow members through our Members' Voices series: 1199SEIUBenefits.org/healthyliving/membervoices. Stop by our Benefits Channel to join webinars on building healthy meals, managing stress and more: 1199SEIUBenefits.org/videos. Visit our YouTube channel to view a wide collection of healthy living videos: youtube.com/@1199SEIUBenefitFunds/playlists. Sample our wellness classes to exercise body and mind: 1199SEIUBenefits.org/wellnessevents.   Guest Bio Kristin Meliambro, MD, is an Associate Professor in the Department of Medicine, Division of Nephrology at the Icahn School of Medicine at Mount Sinai. She earned her medical degree from the Icahn School of Medicine at Mount Sinai, and she completed both her internal medicine residency and clinical and research nephrology fellowships at the Mount Sinai Hospital. In addition to treating patients with a wide range of kidney diseases in diverse clinical settings, Dr. Meliambro is an NIH-funded physician-investigator who conducts basic and translational research with a focus on mechanisms of kidney podocyte injury and novel disease therapies. She is the co-Director of the Nephrology Division's Renal Biorepository, which banks biological specimens and collects clinical data from patients starting at the time of kidney biopsy and continuing longitudinally. She also actively participates as a PI and Co-Investigator in clinical trials testing novel agents for glomerular diseases. Dr. Meliambro also has a strong record of research mentorship of Associate Researchers and graduate/medical students in her lab, the majority of whom have been women and from under-represented minorities in science and medicine. Dr. Meliambro sees patients with a variety of kidney diseases, and she has a particular clinical interest in glomerular diseases. Her clinical responsibilities include the care of outpatients at the Mount Sinai Doctors nephrology practice, hemodialysis patients at Central Park Dialysis Center and inpatients at the Mount Sinai Hospital, where she also teaches and supervises nephrology fellows on the inpatient nephrology services.

You Can't Retire From Purpose Dr. Alan Rozanski on the Six Domains of Health and What It Really Means to Age Well In this episode, I sit down with Dr. Alan Rozanski — cardiologist, lifestyle medicine physician, professor at the Icahn School of Medicine at Mount Sinai, and a founding pioneer of behavioral cardiology. With nearly 300 published articles, Dr. Rozanski has spent 40 years studying how our physical and mental behaviors shape heart health.What We CoverThe Aha Moment. Forty years ago, Dr. Rozanski watched patients' heart function deteriorate while simply talking about stress — just as it would on a treadmill. That observation launched a career exploring the mind-body connection.The Six Domains of Health.Physical Health — Exercise, resistance training, sleep, and nutrition. After 30, we lose 3–8% of muscle mass per decade. Resistance training can slow that decline.Mindset — Optimists live longer and show better biological markers. Gratitude costs nothing but attention.Emotional Well-Being — Chronic depression is one of the heart's greatest threats. Happiness builds resilience and extends life.Social Connection — The size and quality of your social network is a powerful predictor of longevity.Sense of Purpose — "You can retire from a job, but you can never retire your need for purpose."Stress Management — Mild challenge stress promotes growth. Toxic, uncontrollable stress damages health. Boredom carries its own quiet risks.The Biology. Mental states translate into physical disease through stress hormones, insulin resistance, inflammation, and even changes in brain structure. The good news: many of these changes are reversible.Mental Clutter. Scattered attention drains energy. Focused work sprints and intentional recovery help protect mental clarity.Healthcare Today. Dr. Rozanski speaks candidly about the geriatrician shortage, confusing nutritional guidelines, eroding doctor-patient time, and AI's emerging role in restoring it.Key Takeaway Health is not the absence of disease — it is vitality. That feeling is available at 19, 60, and 99. The six domains are six doorways. Wherever you are, one of them is a place to start.Connect with Dr. Rozanski Website: alanrozanski.com | LinkedIn: Dr. Alan RozanskiConnect with Dr. Alan Rozanski

In this episode, UROONCO BCa chief editor Dr Benjamin Pradere (France) sits down with Matthew Galsky, Professor of Medicine at Icahn School of Medicine at Mount Sinai (New York, USA), to discuss the newly published results of the KEYNOTE-B15 trial.This marks a truly pivotal moment for muscle-invasive bladder cancer. The presentation of KEYNOTE-B15 represents one of the most practice-changing advances in localised MIBC management in recent years, opening a new era of peri-operative systemic therapy and renewed hope for our patients.KEYNOTE-B15 is a randomised phase III trial evaluating peri-operative enfortumab vedotin plus pembrolizumab in cisplatin-eligible patients with MIBC. In this in-depth discussion, Prof. Galsky walks us through the scientific rationale behind the study, the key efficacy and safety results, and crucially, how these data are likely to reshape clinical practice, not only in the immediate future but for years to come.A must-listen conversation for urologists and multidisciplinary teams involved in the care of bladder cancer patients.The KEYNOT-B15 study will be also presented and discussed at upcoming EAU26 on Saturday 14th March in the Game Changer Session. Don't miss the chance to hear more on this important study and mark your agenda! This interview was recorded at ASCO GU26. For more updates on bladder cancer, please visit our educational platform UROONCO BCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Dr. Lakshmi Rajdev and Dr. Manish Shah join the podcast to discuss the updated guideline on immunotherapy and targeted therapy in unresectable locally advanced, advanced, or metastatic gastroesophageal cancer. They share first-line and subsequent-line recommendations for both gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma based on actionable biomarkers including PD-L1 expression, MMR and/or MSI, CLDN18.2 expression, and HER2 status. They note the importance of the algorithms and tables in the guidelines that provide visual illustrations and quick reference guides of the evidence-based recommendations. They also comment on ongoing and recently presented trials that may impact future guidelines in this space. Read the full guideline, "Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update" at www.asco.org/gastrointestinal-cancer-guidelines" TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/gastrointestinal-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02958      Timestamps ·       00:00 – 02:15 Introduction and Overview ·       02:16 - 08:20 First-line treatment for patients with pMMR/MSS, HER2-negative gastroesophageal adenocarcinoma ·       08:21 –10:29 First-line treatment for patients with pMMR/MSS, HER2-positive gastroesophageal adenocarcinoma ·       10:30 – 14:39 First-line treatment for patients with dMMR/MSI-H, gastroesophageal adenocarcinoma ·       14:40 – 18:03 First-line treatment for ESCC ·       18:04 – 22:04 Second- and third-line therapy for gastroesophageal adenocarcinoma and ESCC ·       22:05 – 24:38 Importance of guideline ·       24:39 – 27:45 Outstanding questions and future research   Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts.   My name is Brittany Harvey, and today I am interviewing Dr. Lakshmi Rajdev from the Icahn School of Medicine at Mount Sinai and Dr. Manish Shah from Weill Cornell Medicine, co-chairs on "Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update." Thank you for being here today, Dr. Rajdev and Dr. Shah. Dr. Lakshmi Rajdev: Thank you. Dr. Manish Shah: Thank you for having us. It is wonderful. Brittany Harvey: And then just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Rajdev and Dr. Shah, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into what we are here today to talk about, Dr. Shah, I would like to start first with what prompted the update to this guideline, which was previously published in 2023, and what is the scope of this updated guideline? Dr. Manish Shah: Yes, terrific. So even in the last few years, the pace of drug development in gastroesophageal cancers has just been astounding. So, what prompted this guideline is actually the practice-changing results for a new biomarker, CLDN18.2 hat was based on the GLOW and SPOTLIGHT studies, as well as a practice-changing study in HER2-positive disease where we added pembrolizumab to trastuzumab and chemotherapy for tumors that are HER2-positive and PD-L1 CPS 1 or greater. And then there were also new studies and new approvals in esophageal squamous cell cancer that you will hear about as well. So there were several studies, overall more than 5,000 patients were reported on, and that led to several new therapies, new indications, and it really necessitated this guideline. Brittany Harvey: Excellent. It is great to hear about all of these exciting updates in this space. So then to next review the key recommendations of this guideline by clinical question that the expert panel addressed. So, Dr. Rajdev, what is the recommended first-line treatment for patients with proficient mismatch repair, microsatellite stable, HER2-negative gastroesophageal adenocarcinoma? Dr. Lakshmi Rajdev: Thank you for that question. So historically, we have sort of used fluoropyrimidine and platinum doublets, which yielded a survival of about one year. More recently, immunotherapy and targeted therapy options have improved outcomes in patients with advanced esophageal and gastric adenocarcinoma, as well as squamous cell carcinoma. Patients with gastric and GE junction adenocarcinoma have a high rate of actionable alterations, so it is imperative that physicians test the following biomarkers upfront so that it can help guide therapy. The markers recommended by the ASCO panel are HER2, MMR or MSI, CLDN18.2, and PD-L1. And also, it was recommended to use NGS if feasible in this patient population. HER2, as we know, is expressed in about 15% to 25% of patients; PD-L1 expression occurs in about 80% of patients; MSI-high, deficient MMR is present in about 5% to 8% of patients; and CLDN18.2 expression is present in about 40% of patients. There is, of course, biomarker overlap. About 13% to 22% of CLDN18.2 patients are also PD-L1 positive. For patients with pMMR or microsatellite stable HER2-negative disease with PD-L1 expression greater than 1 and absence of CLDN18.2, the panel recommended a first-line therapy with fluoropyrimidine and platinum-based therapy in combination with immunotherapy. These recommendations stem from large phase 3 trials, and the agents approved in the United States are pembrolizumab, nivolumab, and tislelizumab. It has been shown that immunotherapy benefit is greater in patients with higher PD-L1 expression, and it is not possible to comment on the individual PD-L1 cutoff scores and sort of identify the optimal PD-L1 cutoff score that sort of balances benefits and harms. But what is recommended is that immunotherapy-based treatments can be offered in patients with a CPS score of greater than 1. With regard to the choice of immunotherapy agents, that is pembrolizumab, nivolumab, or tislelizumab, these agents are considered to have similar efficacy, and the selection of an agent could be based on dosing schedule, cost considerations, toxicity, and the method of administration. Typically, clinicians should avoid withholding the start of chemotherapy while awaiting biomarker testing, depending on the clinical scenario. Now, for patients with pMMR microsatellite stable disease that is HER2-negative with PD-L1 expression less than 1 and positive CLDN18.2 expression, zolbetuximab-based treatments or in combination with chemotherapy is recommended, and this is based on two global phase III randomized controlled trials, the GLOW and the SPOTLIGHT. And across both studies, the hazard ratio for the overall survival was 0.78, and similarly, there was also an improvement in progression-free survival favoring the zolbetuximab group compared to the chemotherapy group alone. An important note is that nausea, vomiting is commonly associated with zolbetuximab-based treatments, and the panel recommended prophylactic antiemetics, adjusting zolbetuximab infusion rates, pausing infusion temporarily, using non-prophylactic antiemetics, and hydration intravenously prior to discontinuation of zolbetuximab-based chemotherapy. So effective handling of the GI-related symptoms with zolbetuximab is recommended prior to discontinuation of therapy. Now, for patients with pMMR microsatellite stable HER2-negative gastric, GE junction adenocarcinoma with PD-L1 expression greater than 1 and CLDN18.2 positivity, the ones with the dual expression with CLDN18.2 as well as PD-L1 chemotherapy, the choice of therapy can be based on the degree of PD-L1 expression, the toxicity profile, the burden of symptoms, and the anticipated improvement in symptoms associated with response to treatment, the patient comorbidities, the prior medical and treatment history. So this decision needs to be made on a case-by-case basis, and these are some of the factors that we suggested that could potentially influence the choice of therapy. For patients with pMMR microsatellite stable disease that is HER2-negative and a PD-L1 expression less than 1 and an absence of CLDN18.2 expression, first-line therapy with fluoropyrimidine and platinum-based chemotherapy is recommended. So you can see we have segmented out patients based on PD-L1 expression, pMMR and microsatellite stable disease expression, and also based on CLDN expression. Brittany Harvey: Absolutely. And that first point you noted, I think is really important, that biomarker testing is really critical for treatment decision-making in this space. So then the next subgroup of patients that the panel looked at, Dr. Shah, what first-line therapy is recommended for patients with proficient mismatch repair, microsatellite stable, HER2-positive gastroesophageal adenocarcinoma? Dr. Manish Shah: So this was an update from a few years ago. So we have known for 15 years now that if you are HER2-positive, you should get trastuzumab plus chemotherapy. That was based on the ToGA trial. And the update now is based on a trial called KEYNOTE-811, where it examined the addition of pembrolizumab to trastuzumab and chemotherapy versus trastuzumab and chemotherapy, and there was a progression-free and overall survival benefit. And again, here, the biomarkers are important. If your CPS PD-L1 is less than 1, we would not recommend Pembrolizumab in that setting, so you would still get trastuzumab and chemotherapy. But if it is 1 or greater, the PD-L1 CPS score, then we do recommend pembrolizumab unless there is a contraindication to immunotherapy. The take-home message really is from the onset of diagnosis, please check your biomarkers. And I will just, it is worth repeating, it is important to check your PD-L1 status, HER2 status, mismatch repair status, and CLDN18.2 status. And then the optimal therapy, and it is outlined in the publication, is really biomarker-driven. We know that if we are able to hit the target that is overexpressed, we are going to have a better outcome. And Dr. Rajdev did mention where there is overlap, there can be a lack of data, and that is where we are with both PD-L1 positive and CLDN positive. Here we do have data in HER2-positive cases where if you are both HER2-positive and PD-L1 positive, you would combine trastuzumab and pembrolizumab for the best outcomes. Brittany Harvey: Understood. I really appreciate you detailing what is most important for each individual biomarker combination that patients may have. So then following that, Dr. Rajdev, what does the expert panel recommend for first-line treatment for patients with esophageal squamous cell carcinoma that is not amenable to definitive chemoradiation? Dr. Lakshmi Rajdev: There are three phase III randomized clinical trials that have influenced practice in patients with esophageal squamous cell carcinoma examining the benefit of immunotherapy in this patient population. The RATIONALE-306 was a randomized trial of tislelizumab plus chemotherapy with platinum and fluoropyrimidine or paclitaxel versus placebo with chemotherapy. And then you have the KEYNOTE-590, which compared pembrolizumab plus chemotherapy versus chemotherapy alone. And then you have CheckMate-648, which included comparisons of nivolumab plus chemotherapy versus nivolumab plus ipilimumab or chemotherapy. And the primary endpoints for these studies were overall survival, and they did look at subgroups with PD-L1 expression. They used TPS score greater than 1% in CheckMate-648 and PD-L1 CPS greater than 10 in KEYNOTE-590. The bottom line is that the overall hazard ratio for overall survival across this patient population was 0.72. So clearly, there is benefit in patients that express PD-L1 CPS greater than 1 for benefit for the addition of immunotherapy. Now, the benefit again in patients with a PD-L1 expression less than 1 remains limited, and so the panel has made a recommendation for using immunotherapy in combination with platinum-based chemotherapy in patients with a PD-L1 greater than 1. Again, we know that it is hard to make recommendations on what PD-L1 cutoffs are recommended in this patient population, meaning that should it be limited to patients with a PD-L1 of 1 to 4 or greater than 10? I think that the general consensus that has been gleaned from the data is that the higher the PD-L1 expression, the greater the benefit. I do want to comment on another option that is available in patients with squamous cell carcinoma compared to adenocarcinoma, and that is the combination of nivolumab and ipilimumab. Now, in CheckMate-648, nivolumab with ipilimumab was also recommended as a treatment option in patients that have a PD-L1 score of greater than 1. There was a survival benefit demonstrated with this combination compared to chemotherapy alone. And an important observation in this study is that, although there was a slightly increased rate in early death, but there was really no significant difference in PFS and OS compared to chemotherapy alone. Importantly, the treatment appeared to be pretty well tolerated by the study population. There was a notable difference in the objective response rate, which was 35% in the nivolumab plus ipilimumab group compared to patients receiving nivolumab and chemotherapy, where it was 53%. So superiority is, so the importance of chemotherapy in patients with esophageal squamous cell carcinoma is to be noted. However, there is no difference in overall survival and progression-free survival when using the combination of nivolumab and ipilimumab, and thus it affords a chemotherapy-free option for this patient population with esophageal squamous cell carcinoma and a CPS with a score of greater than 1. Brittany Harvey: Understood. I appreciate you reviewing the evidence underpinning those recommendations as well. So then the next patient population that the guideline panel addressed, what first-line therapy is recommended for patients with deficient mismatch repair, microsatellite instability-high, gastroesophageal adenocarcinoma or esophageal squamous cell carcinoma? Dr. Lakshmi Rajdev: The rate of MSI-high expression is about 3% to 7% across different studies. Now, the KEYNOTE-158 was a tumor-agnostic study in patients with non-colorectal cancers, and again, the problem with the MSI-high population, given that it is so rare, the numbers in the individual studies are fairly small. But consistent outcomes do emerge, indicating high response to immunotherapy. So in KEYNOTE-158, a response rate of about 46% was noted. The number of patients was small, it was about 24. In CheckMate-649, which is a study of chemotherapy plus or minus nivolumab in patients with advanced gastric adenocarcinoma, there was again a very small number of patients, and patients that were MSI-high or deficient MMR did experience substantial benefits with the addition of immunotherapy, with hazard ratios in the order of about 0.38. In KEYNOTE-062, again, it was a very small number of patients, again about 6% or so, and similar to CheckMate-649, a substantial benefit was noted in combination with chemotherapy, but also there were benefits noted with pembrolizumab alone. The RATIONALE-305 again was a study of tislelizumab in combination with chemotherapy and similarly showed benefits to the combination of chemotherapy plus immunotherapy in this patient population. I think that we are all aware of the dramatic benefits of immunotherapy in this particular subset of patients, deficient MMR MSI-high, and also we have seen in CheckMate-649 they did have a subset of patients that received nivolumab and ipilimumab. And in this patient population, they noted unstratified hazard ratio of 0.28. So I think that the overall consensus is that immunotherapy is a very important treatment modality in patients with deficient MMR MSI-high disease, given that a lot of the trials in gastroesophageal adenocarcinoma have utilized chemotherapy-based options, that is certainly a recommendation of the panel to use chemotherapy in combination with immunotherapy. However, on a case-by-case basis, the panel recommended immunotherapy alone as well, and given the high response rates noted in trials across different diseases as well as noted in this disease as well. Brittany Harvey: Certainly. And I appreciate you both for reviewing these first-line recommendations. So moving to later lines of therapy, Dr. Rajdev, what recommendations did the expert panel make for second or third-line therapy for gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma? Dr. Lakshmi Rajdev: So, I think that the RAINBOW trial that investigated the utility of the addition of ramucirumab as second-line therapy has been around since 2014, and those results have led to the addition of ramucirumab to taxane-based therapy in the second-line setting. Based on the utilization of oxaliplatin and platinum-based therapy in the front-line setting, there may be patients that have an underlying neuropathy, and so we wanted to really include treatment options for this patient population so that an agent that is less neurotoxic could also be recommended in combination with ramucirumab. The RAMIRIS trial is one such trial where ramucirumab was combined with FOLFIRI, and it demonstrated benefit in combination with ramucirumab. So we have listed that as a potential treatment option for patients in the second-line setting who may have an underlying neuropathy or even for whatever reason that based on the toxicity profile, that needs to be the preferred option by a physician, that recommendation is new from the older guidelines that we have. With regard to the utility of PD-1 inhibitors, there really has been no benefit noted in the second-line setting with regard to overall survival or progression-free survival, so no recommendation is made for that option. I think an important study that has been recently presented is the DESTINY-Gastric04 trial, which really has been practice-changing and has led to the recommendation for trastuzumab deruxtecan in patients that have HER2-positive metastatic gastric or GE junction adenocarcinoma. Now, this is a phase III trial in patients who retained HER2-positive disease after progressing on front-line trastuzumab-based treatments, and the comparator for this trial was trastuzumab deruxtecan versus ramucirumab plus paclitaxel. There was significant improvement and progression-free survival in patients that received trastuzumab deruxtecan. The patients that were excluded from the trial are patients that have pulmonary problems, interstitial lung disease; that is one of the toxicities of this particular agent, and close monitoring and prompt initiation of therapy such as glucocorticoid treatment in patients who develop this toxicity was also highlighted by the panel. So to summarize, the new guidelines highlight the possibility of FOLFIRI plus ramucirumab as a second-line option and then trastuzumab deruxtecan as a later-line option in patients that still retain HER2 expression. And that is very important because the trial did retest patients whether they expressed HER2. As we know, in a substantial number of patients, there is downregulation of HER2, and there is emerging data that the benefit for subsequent HER2-directed therapies is best noted in patients that still retain HER2 expression. Brittany Harvey: Great. So as our listeners have heard, there are many recommendations and new treatment options for advanced gastroesophageal cancer. Dr. Shah, earlier you highlighted the importance of biomarker testing, but I would like to hear in your view, what is the importance of this guideline and how will it impact both clinicians and patients with gastroesophageal carcinoma? Dr. Manish Shah: So as we have discussed throughout this podcast, the treatment for gastroesophageal cancer, both adenocarcinoma and squamous cell cancer, is increasingly complex, increasingly biomarker-driven. And I think the value of the guideline is to place all of that into context. So it provides the data for why certain biomarkers are important, what therapies should be indicated. Not only that, but if you are able to review the guideline, it provides the details of each of these studies and summarizes them in a meta-analysis fashion to sort of give you the context, because sometimes the individual studies can be maybe a little bit discordant or confusing and the guideline attempts to harmonize all that. And then also, I think the tables are very, very interesting because they give you actual numbers in terms of how many patients over a thousand would this benefit or how many patients over a thousand would this cause harm in terms of nausea, vomiting, or other things like that. So it gives you context for helping clinicians and patients weigh the potential benefits of the novel treatment strategies against the potential adverse events. And then finally, the guideline does also provide an algorithm that you are able to follow based on the biomarkers, and those are in figures 4 and 5. So I think overall, it is a very comprehensive guideline. It intends to make more manageable a very complex subject, and you know, I really encourage our listeners to review it after listening to the podcast. Dr. Lakshmi Rajdev: If I can add to that, I think that what is also really good about the guidelines is there are quick summaries. So if someone is busy in the clinic, of course, there is the opportunity to review the data supporting the guidelines in great depth in the manuscript, but what is also really good is that there are good summaries. In the event that you are very busy, you can easily identify what the recommendations should be for that particular patient based on these summaries. Brittany Harvey: Absolutely. Listeners are encouraged to review the full guideline, including those tables and figures that may be more helpful when they are looking for something quick to look at in the clinic as well. So, as you both mentioned, there have been a number of recent practice-changing trials in this area. So I imagine there is still a lot of ongoing research as well. So Dr. Shah, what are the outstanding questions regarding treatment options for patients with locally advanced unresectable, advanced, or metastatic gastroesophageal carcinoma? Dr. Manish Shah: I think we touched upon it a little bit. The guidelines are based on the data available, and they are primarily examining one novel therapy with chemotherapy in a specific biomarker population. But as you know, the biomarkers are not either/or; you are not either CLDN18.2 positive or PD-L1 positive. A portion of patients could have dual biomarkers, and you know, I think that we are generating data on how to manage those patients. At the recent GI Symposium in January this year, the ILUSTRO trial was presented by Dr. Shitara, which looked at combining zolbetuximab and chemotherapy with immunotherapy for dual-positive biomarkers, and that is leading to a phase III study that has begun to enroll. So unanswered questions are: how do we manage dual-positive biomarkers? The other thing that was mentioned is that the current data for mismatch repair deficiency involve chemotherapy plus immunotherapy. Only squamous cell cancer is there a study with a positive non-chemotherapy kind of backbone, that is CheckMate-648 that Dr. Rajdev mentioned. As we move forward, it will be good to get data on non-chemotherapy options in certain biomarker-positive populations. And then finally, another update, which is likely to be practice-changing, is the HERIZON-GEA-01 study that looked at zanidatamab, which is another biparatopic antibody that targets HER2, and that is likely to change practice. And as that data gets published, we may look to even do a rapid update for the current immunotherapy and targeted therapy guideline that is just being published. Dr. Lakshmi Rajdev: So, if I can add to that, there are numerous ADCs that look very interesting. There are bispecific antibodies; in fact, the zanidatamab is a bispecific antibody showing improved activity in patients with HER2-positive disease. So I think there are studies from Asia looking at CLDN CAR T-based therapies. So, I think that there are a lot of novel agents and a lot of excitement in the field. We know that the bemarituzumab study, unfortunately, the FGFR2 inhibitor failed to demonstrate any benefit, but I think that there are other agents that are being explored, so there are newer targets, newer agents, ADCs, bispecifics that could potentially change the field in the future. Brittany Harvey: Yes, we will look forward to the data to address these unanswered questions and new agents and inform future guideline updates. So, I would like to thank you both for all of your work to review the evidence here and update this important guideline, and for your time today, Dr. Rajdev and Dr. Shah. Dr. Lakshmi Rajdev: Thank you. Dr. Manish Shah: Thank you. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/gastrointestinal-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Biologics have changed how patients with asthma are able to handle their symptoms and prevent them from getting worse. Host Amy Attaway, MD, Cleveland Clinic, talks with Monica Kraft, MD, Icahn School of Medicine at Mount Sinai, and De De Gardner, DrPh, Allergy and Asthma Network and member of PAR about depemokimab, the newest biologic for those with severe asthma. Learn how this novel treatment is used once every six months to improve patient outcomes, as well as the research behind this biologic and the future of asthma treatment. Read Dr. Kraft's paper on depemokimab: https://journal.chestnet.org/article/S0012-3692(25)00855-4/pdf  Editor's note: During this episode, Dr. Kraft mistakenly said that depemokimab was approved for treating nasal polyps. Please note that depemokimab is not approved for treating this condition. 

This episode features a highlighted segment from the ROI Centered Care Virtual Summit, produced by Bright Spots Ventures in partnership with TytoCare and the American Telemedicine Association. In this conversation, Eric Glazer sits down with Fernando Carnavali, MD, Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Chief of General Internal Medicine at Mount Sinai Health System, to explore how large academic health systems can translate patient experience, diagnostics, and technology innovation into measurable ROI. Rather than focusing on new tools for their own sake, Dr. Carnavali reframes the challenge: how to use existing data, connected devices, and AI-enabled diagnostics to improve the full patient journey, before, during, and after the visit while also supporting a stretched clinical workforce. Drawing on Mount Sinai's real-world operating environment, the conversation explores how experience, communication, and clinical efficiency are increasingly inseparable from financial performance, especially in inpatient and general internal medicine settings. This discussion moves beyond pilot thinking to address what it takes to operationalize innovation at scale inside a complex health system. What you'll learn in this episode: Why patient experience is a longitudinal journey, not a post-visit survey score How Mount Sinai is using technology and diagnostics to strengthen communication, not replace clinicians The role of AI and connected devices in improving both patient and provider experience Why workforce constraints in primary and general internal medicine demand new care models How health systems can focus on what's already within their control to drive ROI Why proving clinical and economic value upfront is essential to scaling innovation About Dr. Fernando Carnavali: Dr. Carnavali is the Chief of the Division of General Internal Medicine for Mount Sinai Morningside and Mount Sinai West (MSM/MSW) and serves as the Medical Director of the Long COVID Satellite Clinic at Mount Sinai Doctors Ansonia (MSD-Ansonia). In this role, Dr. Carnavali oversees a large, complex division with eight outpatient service locations spanning Manhattan's West Side from Harlem to Chelsea. Clinically, he focuses on the treatment and management of chronic illness, with a particular emphasis on Long COVID care. In early 2020, Dr. Carnavali led MSM/MSW's outpatient response to the COVID-19 pandemic, organizing early testing and triage for community patients and serving for eight weeks on the inpatient COVID units—an experience that provided firsthand insight into the impact of SARS-CoV-2 in New York City. In May 2021, he coordinated the launch of the Long COVID Clinic at MSD Ansonia and continues to personally evaluate new and ongoing patients each week. Committed to sharing Mount Sinai's expertise in Long COVID care, Dr. Carnavali has participated in numerous national and international forums, training providers in this emerging field. He has also built a strong media presence, spotlighting both the Ansonia clinic and the Mount Sinai Long COVID program to raise public awareness. Since 2024, he has served as Co-Principal Investigator on a grant from the Agency for Healthcare Research and Quality (AHRQ) and the Department of Health and Human Services titled "Evaluation of Long COVID Care Practices." In addition to Long COVID work, Dr. Carnavali leads outpatient practice transformation initiatives across MSM/MSW and the Mount Sinai Health System, guiding quality improvement teams to enhance patient satisfaction, improve access to care, and explore innovative service models.   Podcast Recommendation: Check out Access Amplified, brought to you by TytoCare and hosted by Joanna Braunold - a podcast about how digital health is helping increase access to care and equity, one innovation at a time. We'll shine a light on what's actually working to make care more accessible and  inclusive. If you're a healthcare leader, an innovator, a policy shaper, or anyone passionate about health equity, this podcast is for you. New episodes drop every two weeks. Follow or subscribe wherever you get your podcasts. https://www.tytocare.com/resources/access-amplified Thank You to Our Episode Partner, TytoCare. TytoCare enables health systems and plans to deliver high-quality remote exams anytime, anywhere. Their FDA-cleared devices and AI-powered diagnostic platform support virtual specialty care, school-based programs, and home health models—reducing unnecessary ED visits and improving patient experience. To learn more, visit tytocare.com. Schedule a Meeting with a Senior Leader at TytoCare: To explore how TytoCare can help your organization expand virtual specialty access and improve care coordination, reach out to jtenzer@brightspotsventures.com  to schedule a meeting. About Bright Spots Ventures: Bright Spots Ventures is a healthcare strategy and engagement company that creates content, communities, and connections to accelerate innovation. We help healthcare leaders discover what's working, and how to scale it. By bringing together health plan, hospital, and solution leaders, we facilitate the exchange of ideas that lead to measurable impact. Through our podcast, executive councils, private events, and go-to-market strategy work, we surface and amplify the "bright spots" in healthcare, proven innovations others can learn from and replicate. At our core, we exist to create trusted relationships that make real progress possible. Visit our website at www.brightspotsinhealthcare.com.  

Our ears, nose, and throat (ENT) work quietly together to shape how we hear, breathe, taste, and even defend ourselves against the outside world. From the often-misunderstood role of earwax to why dry air and seasonal changes make nosebleeds more common—and how inflammation and mucosal irritation contribute to sore throats—many everyday ENT issues are actually signs of smart protective design. But with such a complex system, how simple can effective treatments really be? Can warm tea with honey actually soothe throat irritation? Are cotton swabs really bad for our ears? Can spicy foods truly clear sinus infections?In this episode, we are joined by Dr. Chris Park, MD (known online as ChrisP.MD), an Otolaryngology (ENT) - Head & Neck Surgery Chief Resident Physician.Dr. Park received his B.A. in Biology and Computer Science from Dartmouth College and his M.D. with Distinction in Research from the Icahn School of Medicine at Mount Sinai, where he was a Researcher at the Laryngology Lab. Dr. Park is currently completing his ENT residency at the Indiana University Department of Otolaryngology-Head and Neck Surgery and recently matched into the Facial Plastic & Reconstructive Surgery Fellowship at the University of Pennsylvania Department of Otorhinolaryngology-Head and Neck Surgery.Online, Dr. Park has amassed over 350,000 followers, beginning his journey on TikTok, sharing his life surrounding medicine.Follow Friends of Franz Podcast: Website, Instagram, FacebookFollow Christian Franz (Host): Instagram, YouTube

Welcome to OncLive On Air®! OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today's episode, we welcomed John O. Mascarenhas, MD, a member of The Tisch Cancer Institute, a professor of medicine at the Icahn School of Medicine, and director of the Center of Excellence for Blood Cancers and Myeloid Disorders at Mount Sinai in New York, New York.In the exclusive interview, Dr Mascarenhas explored novel targeted therapeutic approaches being evaluated in patients with myeloproliferative neoplasms, including myelofibrosis and polycythemia vera. He outlined key reasons for investigating non–JAK inhibitor agents within this treatment paradigm; outlined data from a pair of phase 1 trials (NCT05936359; NCT06034002) evaluating the INCA033989 as monotherapy or in combination with ruxolitinib (Jakafi) in patients with CALR exon 9–mutated myelofibrosis; detailed another ongoing phase 1 study (NCT06313593) looking at INCB160058 in patients with MPNs; and explained how investigational targeted therapies could ultimately impact the MPN treatment paradigm.

In this week's episode, both of our storytellers find themselves reckoning with the choices they've made—discovering how a single decision, whether made years ago or in the chaos of a crisis, can shape who we become and the responsibilities we carry.Part 1: When Misha Gajewski's grandfather has a stroke while the rest of her family is out of town, she suddenly becomes the emergency contact.Part 2: After learning that her mother gave up on her dream of becoming a musician, Paula Croxson vows never to give up on her dream of being a scientist.Misha Gajewski is the artistic director and host of The Story Collider podcast. She is also a freelance journalist, educator, and copywriter. Her work has appeared on Vice, Forbes, blogTO, CTV News, and BBC, among others. She's the co-found of the world's first 24-hour True Storytelling Festival and a proud cat mom. She has also written scripts for the award-winning YouTube channel SciShow. Dr. Paula Croxson is a neuroscientist, award-winning science communicator and storyteller. She is a Senior Producer at The Story Collider and the President of the Board of Directors. In her day job, she is President at Stellate Communications where she supports academic and nonprofit science communication. Paula has an M.A. from the University of Cambridge and a M.Sc. and a Ph.D. from the University of Oxford. She was an Assistant Professor of Neuroscience and Psychiatry at the Icahn School of Medicine at Mount Sinai for 5 years before shifting her career focus to science communication and public engagement with science, first at Columbia University and then at the Dana Foundation. She is passionate about communicating science in meaningful and effective ways, and fostering diversity, equity, inclusion and accessibility in science. She is also a musician, playing flute in several rock bands, and a long-distance open water swimmer. The swimming is apparently for “fun”. You can learn more about her at paulacroxson.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome back to OccPod! This episode features a conversation with someone who has helped shape how physicians across the country understand and apply impairment ratings, Dr. Douglas Martin.Dr. Martin is a Past President of ACOEM and is a board-certified Family Medicine physician specializing in Occupational and Environmental Medicine. Dr. Martin's areas of expertise include workers' compensation injuries, aviation and commercial driver evaluations, fitness-for-duty determinations, independent medical exams, and file reviews. He also serves as co-chair of the AMA Guides Editorial Panel, leading national efforts to modernize and standardize impairment rating.Our host is Dr. Ismail Nabeel, professor in the Department of Environmental Medicine and the Department of Artificial Intelligence and Human Health at the Icahn School of Medicine at Mount Sinai. Dr. Nabeel is an ACOEM Fellow and serves on the ACOEM Board of Directors.In this episode, Dr. Martin breaks down the long and sometimes surprising history of impairment and disability, explains how the AMA Guides have evolved, and shares what's new in the 2024 digital updates – especially the major changes to the musculoskeletal chapters. He also reflects on artificial intelligence, transparency in guideline development, and what these updates mean for physicians, patients, and the future of equitable compensation.

My conversation with Dr Emanuel begins at about 34 minutes Subscribe and Watch Interviews LIVE : On YOUTUBE.com/StandUpWithPete ON SubstackStandUpWithPete Stand Up is a daily podcast. I book,host,edit, post and promote new episodes with brilliant guests every day. This show is Ad free and fully supported by listeners like you! Please subscribe now for as little as 5$ and gain access to a community of over 750 awesome, curious, kind, funny, brilliant, generous soul In Eat Your Ice Cream, renowned health expert Dr. Ezekiel J. Emanuel argues that life is not a competition to live the longest, and that "wellness" shouldn't be difficult; it should be an invisible part of one's lifestyle that yields maximum health benefits with the least work Ezekiel J. Emanuel, MD, PhD, is the Vice Provost for Global Initiatives, the Co-Director of the Healthcare Transformation Institute, and the Diane v.S. Levy and Robert M. Levy University Professor at the University of Pennsylvania Perelman School of Medicine. Emanuel is an oncologist and world leader in health policy and bioethics. He is a Special Advisor to the Director General of the World Health Organization, Senior Fellow at the Center for American Progress, and member of the Council on Foreign Relations.  He was the founding chair of the Department of Bioethics at the National Institutes of Health and held that position until August of 2011. From 2009 to 2011, he served as a Special Advisor on Health Policy to the Director of the Office of Management and Budget and National Economic Council. In this role, he was instrumental in drafting the Affordable Care Act (ACA). Emanuel also served on the Biden-Harris Transition Covid Advisory Board. Dr. Emanuel is the most widely cited bioethicist in history.  He has over 350 publications and has authored or edited 15 books. His recent publications include the books Which Country Has the World's Best Health Care (2020), Prescription for the Future (2017), Reinventing American Health Care: How the Affordable Care Act Will Improve our Terribly Complex, Blatantly Unjust, Outrageously Expensive, Grossly Inefficient, Error Prone System (2014) and Brothers Emanuel: A Memoir of an American Family (2013). In 2008, he published Healthcare, Guaranteed: A Simple, Secure Solution for America, which included his own recommendations for health care reform. Dr. Emanuel regularly contributes to the New York Times, the Washington Post, the Wall Street Journal, The Atlantic, and often appears on BBC, NPR, CNN, MSNBC and other media outlets. He has received numerous awards including election to the National Academy of Medicine, the American Academy of Arts and Sciences, the Association of American Physicians, and the Royal College of Medicine (UK). He has been named a Dan David Prize Laureate in Bioethics, and is a recipient of the AMA-Burroughs Wellcome Leadership Award, the Public Service Award from the American Society of Clinical Oncology, Lifetime Achievement Award from the American Society of Bioethics and Humanities, the Robert Wood Johnson Foundation David E. Rogers Award, President's Medal for Social Justice Roosevelt University, and the John Mendelsohn Award from the MD Anderson Cancer Center. Dr. Emanuel has received honorary degrees from Icahn School of Medicine at Mount Sinai, Union Graduate College, the Medical College of Wisconsin, and Macalester College. In 2023, he became a Guggenheim Fellow. Dr. Emanuel is a graduate of Amherst College. He holds a M.Sc. from Oxford University in Biochemistry, and received his M.D. from Harvard Medical School and his Ph.D. in political philosophy from Harvard University. On YOUTUBE.com/StandUpWithPete ON SubstackStandUpWithPete   Listen rate and review on Apple Podcasts Listen rate and review on Spotify Pete On Instagram Pete on Blue Sky Pete on Threads Pete on Tik Tok Pete on Twitter Pete Personal FB page Stand Up with Pete FB page All things Jon Carroll  Gift a Subscription https://www.patreon.com/PeteDominick/gift Send Pete $ Directly on Venmo  

In this STS blog article, Shubham Gulati, a third-year medical student at the Icahn School of Medicine at Mount Sinai, reflects on a transformative year with his mentor, Dr. Ravi Rajaram, and other accomplished surgeons, who created space for candid discussions about the realities and rewards of becoming a cardiothoracic surgeon.

In this episode, Michael S. Smith, MD, MBA, Associate System Chief of Gastroenterology for Clinical Operations and Strategic Planning at The Mount Sinai Health System and Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai, discusses key trends in GI care, late cancellations, telehealth, AI adoption, and how strong leadership and culture can support both providers and patients.

In this episode, Ashutosh (Ash) K. Tewari, MD, Urologist and Prostate Cancer Specialist and Chairman of the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai, discusses the rise in prostate cancer cases, strategies to reduce treatment-related side effects, and how mobile units are expanding outreach to improve patient access and early detection.

In today's skin-obsessed world, we are met with ever-emerging beauty trends, viral products, and buzzy cosmetic treatments that aim to do one thing: delay and reverse the dermal signs of aging, while preserving and nourishing the skin barrier. From beef tallow to NAD+ IV therapy to rosemary oil for hair loss and even what seems to be more benign marketing like "clean beauty" claims, how can we determine what truly keeps skin healthy versus what's simply trending?In this episode, we are joined by Dr. Connie Yang, MD, FAAD. Dr. Yang is a board-certified dermatologist and clinical assistant professor of medicine based in New York City. Dr. Yang received her MD from Boston University School of Medicine, spent a dedicated research year focused on pigmentary disorders at Massachusetts General Hospital/Harvard Medical School Department of Dermatology, and completed her Dermatology residency at Icahn School of Medicine at Mount Sinai, where she served as Chief Resident of Cosmetics in her final year. Currently, Dr. Yang serves as a physician at PFRANKMD by Dr. Paul Jarrod Frank and an assistant clinical professor at the Icahn School of Medicine Department of Dermatology. Dr. Yang has been featured on Vogue, ELLE, Cosmopolitan, Popsugar, The New York Post, Allure, NBC News, Well+Good, and RealSelf.Follow Friends of Franz Podcast: Website, Instagram, FacebookFollow Christian Franz (Host): Instagram, YouTube

ECMO is the topic of this week's episode of Pediheart. We speak with Assistant Professor of Pediatrics and cardiac critical care specialist at Northwell Health, Dr. Ivana Capin about a recent ELSO database study she conducted to assess outcomes in single ventricle patients who were treated with ECMO prior to single ventricle palliation. What factors were associated with worse overall outcomes? Can this therapy be used to stabilize the HLHS patient with an intact atrial septum? Why have outcomes for this high risk patient group not appreciably improved in the recent decade? How can these data improve prognostic clarity when speaking with families in this difficult situation.Also joining us briefly is Associate Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai, Dr. Scott Aydin to discuss his co-author and mentor, Dr. George Ofori-Amanfo as we approach the 4th anniversary of his untimely and tragic passing. DOI: 10.1017/S1047951125001386

Danielle and Whitney sit down with Dr. Elizabeth Sharp, a board-certified Internal and Obesity Medicine physician, functional medicine practitioner, and founder of Health Meets Wellness and The TouchCare Method. Together, they explore how dramatically the GLP-1 landscape has evolved—from early use in diabetes and clinical obesity to widespread microdosing, off-label protocols, emerging oral versions, and new research on inflammation, dementia risk, PCOS, and IBD. Dr. Sharp breaks down what the science actually says, who these medications can help, and the real considerations we all should be talking about. Dr. Sharp shares:  What GLP-1 medications actually do in the body Why food noise is different from food addiction The critical role of diet, protein, fiber, and movement on GLP-1s How to protect muscle mass and metabolic health GLP-1 use during perimenopause and menopause She also dives into the importance of resistance training, daily strength “snacks,” and the rising role of creatine for women, cognition, and anyone on GLP-1s. Dr. Sharp leaves us with a powerful piece of lightwork you can integrate immediately—wherever you are in your health journey. Check out the video version on the Sakara Life YouTube channel here: https://youtu.be/ZA3Knfq7NCY  Elizabeth Sharp Edens, M.D., DABOM, IFMCP is a board-certified Internal Medicine and Obesity Medicine physician, an Institute for Functional Medicine Certified Practitioner, and the founder of Health Meets Wellness and The TouchCare Method. She created Health Meets Wellness to make functional, root-cause medicine more accessible — blending evidence-based clinical care with movement, nutrition, and lifestyle medicine to help patients achieve lasting wellness. A certified yoga instructor, she weaves daily movement practices into treatment plans, believing medicine works best when paired with mindful physical activity. Building on her clinical work, Dr. Sharp launched The TouchCare Method, an innovative digital obesity medicine and weight-management platform offering high-touch, wrap-around care both in-person and online. The platform integrates medical treatment, nutrition, exercise, behavioral health, and data-driven insights into one comprehensive program — providing patients with continuous support through virtual coaching, AI-enhanced engagement, and remote monitoring. Dr. Sharp developed the Health Meets Wellness Method in collaboration with Troy Flanagan, Ph.D., and Susie Parker-Simmons, RDN, to address metabolic health through a multifaceted, personalized approach. Her work focuses on treating obesity as a chronic disease—combining medication management with individualized nutrition, physical activity, and behavioral strategies for sustainable results. She also serves as an Assistant Professor at the Icahn School of Medicine at Mount Sinai. She graduated Magna Cum Laude from St. George's University School of Medicine and completed her internal medicine residency at Lenox Hill Hospital. She went on to practice with Mount Sinai Doctors, where she received the Cullman Family Award for Excellence in Physician Communication, and later worked at One Medical.

How do we build a healthcare system where physicians and healthcare professionals can not only survive but truly thrive? In this illuminating episode of Life Changing Moments, host Dr. Dael Waxman sits down with a pioneer in the field, Dr. Jonathan Ripp, Chief Wellness Officer at the Icahn School of Medicine at Mount Sinai and co-founder of CHARM (the Collaborative for Healing and Renewal in Medicine). Dr. Ripp traces his 25-year journey from studying physician identity formation in residency to leading a national movement focused on structural well-being. He provides a masterclass on the evolution of the physician well-being movement, explaining why we've moved beyond individual "resilience" to address systemic issues like work design, clerical burden, and organizational culture. We dive deep into the genesis and mission of CHARM, the professional society for healthcare well-being leaders, and explore its foundational charter that has become a blueprint for institutions nationwide. Discover the most promising interventions today, from the explosive growth of physician coaching to the potential of AI and ambient scribes to reclaim time for meaningful work. In this episode, you'll learn: The story behind the CHARM collaborative and how it creates community for well-being leaders. Why the CHARM charter remains a critical document for defining the principles of systemic well-being. The four key domains of effective well-being programs: mental health, individual strategies, leadership culture, and work design. Why physician coaching and AI tools are among the most exciting advancements for reducing burnout. Practical advice for medical students and early-career physicians on how to choose a workplace that will support their well-being. Dr. Ripp's vision for a future where addressing healthcare worker well-being is a consistent, standardized priority across all health systems. If you are a physician, healthcare leader, medical student, or anyone passionate about healing the healers, this conversation is a source of grounded hope and a clear-eyed look at the path forward. Mentioned in this episode: CHARM: The Collaborative for Healing and Renewal in Medicine Connect with Us: Subscribe to Life Changing Moments for more conversations on finding purpose and success in medicine. What is the most pressing well-being challenge in your organization? Share your thoughts in the comments below! Chapters: 0:00 - Meet a Pioneer in Physician Well-Being 3:22 - Dr. Ripp's 25-Year Journey from Resident to CWO 7:10 - The "Transformation" of Physicians in Training 12:16 - The Birth of the CHARM Collaborative 15:08 - The CHARM Charter: A Blueprint for Well-Being 18:47 - The State of Physician Well-Being Today 25:05 - Most Promising Interventions: Coaching & AI 27:22 - The Future of Healthcare Well-Being in 5 Years 29:47 - Advice for the Next Generation of Physicians 33:58 - Final Thoughts: Perseverance and Community Keywords: Physician Well-Being, Doctor Burnout, CHARM, Collaborative for Healing and Renewal in Medicine, Dr. Jonathan Ripp, Chief Wellness Officer, Mount Sinai, Physician Coaching, Healthcare Leadership, Physician Identity, Medical Resident Burnout, Structural Change, Work Design, Clerical Burden, Electronic Health Record, EHR, AI in Medicine, Ambient Scribing, Physician Retention, Healthcare Culture, Organizational Culture, Mental Health, Resilience, Life Changing Moments, MD Coaches, Dr. Dael Waxman, Joy in Medicine, ACGME, AMA, Lorna Breen Foundation.   -+=-+=-+=-+= Join the Conversation! We want to hear from you! Do you have additional thoughts about today's topic? Do you have your own Prescription for Success? Record a message on Speakpipe   Unlock Bonus content and get the shows early on our Patreon Follow us or Subscribe: Apple Podcasts | Google Podcasts | Stitcher | Amazon  | Spotify --- There's more at https://mymdcoaches.com/podcast Music by Ryan Jones. Find Ryan on Instagram at _ryjones_, Contact Ryan at ryjonesofficial@gmail.com Production assistance by Clawson Solutions Group, find them on the web at csolgroup.com

Dr. Hoffman continues his conversation with Dr. Alan Rozanski, a distinguished Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Director of Nuclear Cardiology at Mount Sinai St. Luke's in New York City.

Dr. Alan Rozanski, a distinguished Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Director of Nuclear Cardiology at Mount Sinai St. Luke's in New York City, details the holistic aspects of medicine, emphasizing the integrative approach involving lifestyle, mental health, exercise, and the psychological dimensions of heart health. Dr. Rozanski reveals the six domains of optimal health and vitality, sharing insights from his pioneering work in integrating such approaches into cardiology, the significant impact of stress, and the importance of maintaining a sense of life purpose and social connections. He also delves into modern imaging techniques, the utility of coronary artery calcium scores, and emerging treatments like GLP-1 drugs for cardiovascular health. The conversation provides a thorough exploration of comprehensive health management strategies beyond just medication and surgery.

Description: In this episode, we'll explore what it means to aim for no compromise in psoriatic arthritis care—addressing both skin and joint symptoms with dermatologist and rheumatologist Dr. Saakshi Khattri and patient advocate Dayna Pham who lives with psoriasis and psoriatic arthritis.   Join moderator Jeff Brown as he asks how patients and their healthcare providers can work in partnership to create a comprehensive, personalized treatment plan that reflects the full impact of psoriatic disease with triple board-certified dermatologist, rheumatologist, and internist Dr Saakshi Khattri, who is also an NPF medical board member, along with Dayna Pham, a patient advocate and volunteer with NPF's advocacy and community engagement teams who is living with psoriasis and psoriatic arthritis. . Whether you're newly diagnosed or navigating long-term care, this conversation is all about advocating for care that supports your whole self—without settling for less.   The intent of this episode is to emphasize the need to be aware of psoriatic arthritis symptoms and once symptoms are present accept no compromise when treating skin and joints to obtain clear skin and painless joints.  This podcast episode is sponsored by UCB. Timestamps: (0:23) Intro to Psoriasis Uncovered and guest welcome dermatologist, rheumatologist, and internist Dr. Saakshi Khattri and Dayna Pham, a patient advocate and medical student living with plaque psoriasis and psoriatic arthritis. (1:38) Psoriasis is more than skin deep with an inflammatory connection between the skin and joints. (3:03) The onset of psoriatic arthritis can be confusing. Healthy skin and joints should be the expectation without having to compromise on life's goals. (4:16) Knowing the association between psoriasis and psoriatic arthritis from the beginning is important to avoid delay in diagnosis and treatment. Be aware of systemic symptoms and discuss risks with a health care provider. (6:18 ) The goal of treatment is to achieve meaningful and lasting improvement in skin and joint symptoms.   (7:56) Treatments have evolved to target known drivers of inflammation in psoriasis and psoriatic arthritis. (8:29) The IL-17 family is a key cytokine with 6 related signaling molecules. IL-17A and F play a role in the inflammatory process related to psoriasis and psoriatic arthritis. (9:48) What discussion about treatment goals could include between a patient and health care provider. (13:19) If you have psoriasis and psoriatic arthritis you should feel empowered to speak up, seek answers, and find a treatment that offers no compromise on achieving clear skin and healthy joints.   Key Takeaways: ·       Psoriasis is an immune mediated disease that results in systemic inflammation that can affect        both the skin and joints. Unfortunately many people do not realize their joint symptoms may          be related to their psoriasis.  ·       The purpose of treatment which uses a variety of mechanisms of action targeting specific cytokines such as TNF-alpha, IL-12/23, IL-23, IL-17 is to achieve meaningful and lasting improvement in skin and joint symptoms. ·       If you have psoriasis and psoriatic arthritis you should feel empowered to speak up, seek answers, and to work with your health care team to identify goals and treatment choices that aim to preserve quality of life. Guest Bios:   Saakshi Khattri, M.D., MAS, is a triple board certified medical dermatologist, rheumatologist, and internist in the greater New York area who serves on the medical board of the National Psoriasis Foundation. She is the Director of the Center for Connective Tissue Diseases at Icahn School of Medicine at Mount Sinai. Dr. Khattri's area of interests include inflammatory and autoimmune skin diseases especially those with a rheumatology/dermatology overlap like psoriasis and psoriatic arthritis.  She is actively involved in research and clinical trials for psoriasis and psoriatic arthritis where she seeks to identify immune pathways that lead to new biomarkers and treatments. Dr. Khattri is extensively published  in peer reviewed journals and is also a member of the International Psoriasis Council.                                                                                                                                                                  ​Dayna Pham is  a patient advocate, medical student, and volunteer with NPF's advocacy and community engagement teams who lives with psoriasis and psoriatic arthritis. Dayna's psoriasis journey began at age 21 when she discovered bumps on her back which became plaques. Within weeks her body was impacted head to toe with plaque psoriasis, at 40% BSA.  After being misdiagnosed and undertreated for a few months she eventually found a dermatologist who diagnosed her with moderate-to-severe plaque psoriasis and prescribed a biologic. She's 25 now and seeks to live her fullest life possible while balancing her psoriasis and psoriatic arthritis. Resources: ·     Learn more about psoriatic arthritis from symptoms, diagnosis, treatment options to      coping with the disease. Ø  ·      Armstrong A, Levit NA, Schneider B, et al. Patient-identified treatment goals for psoriatic                 disease: Results from a US patient survey.  J Psoriasis Psoriatic Arthritis. 2025;10(1):1–11.    

Money is a tool. Freedom is the goal. A plan is the bridge. Join us for a powerful conversation with Dr. Latifat Akintade, a board-certified gastroenterologist, founder of MoneyFitMD and The Money Coaching School for Women Physicians, bestselling author of The Power to Choose and Done With Broke, and host of the MoneyFitMD Podcast.We will cover the mindset and mechanics that help women physicians achieve true financial freedom without losing wellness or identity. Learn how to create a simple money plan, pay off six-figure debt, grow your net worth, and invest with confidence. Discover how to align money choices with your values, career, and life.About Dr. LatifatDr. Latifat Akintade trained at the University of California, Davis School of Medicine, completed Internal Medicine residency at the Icahn School of Medicine at Mount Sinai and Mount Sinai Hospital, and pursued Gastroenterology fellowship at the University of California, San Francisco School of Medicine. She is board certified in Gastroenterology by the American Board of Internal Medicine. As the visionary behind MoneyFitMD and The Money Coaching School for Women Physicians, she blends clinical expertise, money coaching, and life coaching to help women physicians build wealth without sacrificing wellness or identity. She is a sought after speaker, an Amazon bestselling author, a dynamic podcast host, and a proud mother of three daughters who loves great books, loud laughs, and ocean views.What you will learnA step by step money plan for women physiciansHow to crush debt and build wealth with clarityInvesting basics that reduce stress and boost confidenceHow to protect wellness while you grow your net worthThe power of choice in career, family, and freedomLearn more.www.moneyfitmd.com